

**PHARMACOLOGY BIOCHEMISTRY
&
BEHAVIOR**

Index to

VOLUME 26 1987

CONTENTS

Editorial vii

Articles

Chronic haloperidol effects on oral movements and radial-arm maze performance in rats.
 LEVIN, E. D., D. M. GALEN and G. D. ELLISON 1

Amphetamine-induced on- and off-wall rearing in adult laboratory rats.
 RUSSELL, K. H., M. GIORDANO and P. R. SANBERG 7

Beta-adrenergic agonists reduce spontaneous motor activity through either β_1 or β_2 receptors.
 FRANCES, H., N. RENWART, S. DANTI, R. CASH, R. RAISMAN and
 P. SIMON 11

Changes in d-amphetamine elicited rotational behavior in rats exposed to uncontrollable footshock stress.
 CARLSON, J. N., S. D. GLICK and P. A. HINDS 17

**Interactions of clonidine with phencyclidine and ketamine:
 Studies of radial maze performance and righting reflex in rats.**
 McCANN, D. J., R. A. RABIN and J. C. WINTER 23

Reinforcement reduces behavioural impairment under an acute dose of alcohol.
 HAUBENREISSER, T. and M. VOGEL-SPROTT 29

**Repeated treatment with antidepressant drugs does not affect the benzodiazepine receptors in
 preincubated membrane preparations from mouse and rat brain.**
 PRZEGALIŃSKI, E., A. ROKOSZ-PELC, L. BARAN and J. VETULANI 35

**Increased self-administration of cocaine following haloperidol:
 Effect of ovariectomy, estrogen replacement, and estrous cycle.**
 ROBERTS, D. C. S., J. C. H. DALTON and G. J. VICKERS 37

**In morphinised rats SKF 38393 converts dopamine D_2 receptor-mediated forward locomotion into
 backward walking.**
 AXON, D. I. R., G. H. FLETCHER and M. S. STARR 45

**Motivational vs. motor effects of striatal and pallidal gabergeric projections to subthalamic and
 entopeduncular nuclei, ventromedial thalamus, and ventral globus pallidus.**
 WILLIAMS, S. F. and L. J. HERBERG 49

β -Endorphin tolerance is inhibited by oxytocin.
 KOVÁCS, G. L. and G. TELEGDY 57

**The effects of ethanol on the offense and defensive behaviors of male and female rats during
 group formation.**
 BLANCHARD, R. J., K. HORI, K. FLANNELLY and D. C. BLANCHARD .. 61

Biphasic dose-response relationship for effects of toluene inhalation on locomotor activity. HINMAN, D. J.	65
Differential convulsive susceptibility of high-activity and low-activity selected mice in response to GABA antagonists. McINTYRE, T. D. and H. P. ALPERN	71
Suppressive effects of intraventricular injected dopamine and nomifensine on muricide induced by thiamine deficiency. ABE, Y., T. TADANO, A. YONEZAWA and K. KISARA	77
Age-dependent changes of brain GABA levels, turnover rates and shock-induced aggressive behavior in inbred strains of mice. CLEMENT, J., S. SIMLER, L. CIESIELSKI, P. MANDEL, S. CABIB and S. PUGLISI-ALLEGRA	83
Protein changes in the rat's prefrontal and "inferotemporal" cortex after exposure to visual problems. MOGENSEN, J. and O. S. JØRGENSEN	89
Co-dergocrine, cerebral glucose utilization and maze performance in middle-aged rats. WALOVITCH, R. C., D. K. INGRAM, E. L. SPANGLER and E. D. LONDON	95
The effects of ethanol on eye tracking in rhesus monkeys and humans. ANDO, K., C. E. JOHANSON and C. R. SCHUSTER	103
A new method for screening anxiolytic drugs in rats. YAMAMOTO, T. and S. UEKI	111
Cholinergic involvement in the action of formetanate on operant behavior in rats. MOSER, V. C. and R. C. MACPHAIL	119
Dopamine autoreceptor antagonists: Effects on sleep-wake activity in the rat. SVENSSON, K., P. ALFÖLDI, M. HAJÓS, G. RUBICSEK, A. M. JOHANSSON, A. CARLSSON and F. OBÁL, JR.	123
Determination of cross tolerance in rat spinal cord using intrathecal infusion via sequential mini-osmotic pumps. LOOMIS, C. W., B. MILNE and F. W. CERVENKO	131
Behavioral effects of THC as a function of environment and prior drug experience. MARTIN, P., W. HODGE, M. ROYAL and B. JONES	141
Differential effects of CGS 8216 and naltrexone on ingestional behaviour. KIRKHAM, T. C., D. J. BARBER, R. W. HEATH and S. J. COOPER	145
A role for serotonin and beta-endorphin in the analgesia induced by some tricyclic antidepressant drugs. SACERDOTE, P., A. BRINI, P. MANTEGAZZA and A. E. PANERAI	153
Effect of pentylenetetrazol-induced convulsions on the development and expression of limbic kindled seizures. GRAMLICH, C. A. and J. S. STRIPLING	159
The interaction of d-amphetamine and naloxone differs for rats trained on separate fixed-interval or fixed-ratio schedules of reinforcement. ANDREWS, J. S. and S. G. HOLTZMAN	167
Cross-tolerance between muscarinic agonists: Role of muscarinic receptors. COLLINS, A. C., T. N. SMOLEN, A. SMOLEN and L. J. MEDHURST	173

VOLUME INDEX

Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. DENOBLE V. J.	183
Brief Communications	
An investigation of the role played by the superior colliculus and ventromedial thalamus in self-injurious behavior produced by intranigral microinjection of muscimol. BAUMEISTER, A. A., G. D. FRYE and L. L. MOORE	187
Naloxone sensitivity in squirrel monkeys under a schedule of shock titration. OLIVETO, A. H. and L. A. DYKSTRA	191
Effects of scopolamine on locomotor activity and metabolic rate in mice. BUSHNELL, P. J.	195
Behaviourally specific interactions between naloxone and beta-phenylethylamine in an operant drug discrimination procedure in rats. GOUDIE, A. J.	199

CONTENTS

Editorial	vii
Articles	
The effect of chronic imipramine and electroconvulsive shock treatment on [³H]DADLE binding to cortical membranes of rats pretreated with chronic reserpine or 6-hydroxydopamine.	
ANTKIEWICZ-MICHALUK, L., J. MICHALUK, A. ROKOSZ-PELC, D. MARONA-LEWICKA and J. VETULANI	203
Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats.	
RODRÍGUEZ ECHANDÍA, E. L., S. T. BROITMAN and M. R. FÓSCOLO ..	207
Rewarding and aversive effects of stimulant drugs in infant rats.	
SMITH, C. A. and E. W. HOLMAN	211
Norepinephrine-mediated suppression of apomorphine-induced aggression and locomotor activity in the rat amygdala.	
PUCILOWSKI, O., E. TRZASKOWSKA, W. KOSTOWSKI and L. VALZELLI	217
Chronic autoreceptor blockade and neuroleptic-induced dopamine receptor hypersensitivity.	
GORDON, J. H., J. K. CLOPTON, J. C. CURTIN and W. C. KOLLER	223
Involvement of brain transmitters in the modulation of shock-induced aggression in rats by propranolol and related drugs.	
RAY, A., M. ALKONDON and P. SEN	229
Mechanism of lithium action: <i>In vivo</i> and <i>in vitro</i> effects of alkali metals on brain superoxide dismutase.	
SHUKLA, G. S.	235
Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.	
WEINER, I., J. FELDON and Y. KATZ	241
Differential effects of benzodiazepine receptor ligands on isotonic saline and water consumption in water-deprived rats.	
ESTALL, L. B. and S. J. COOPER	247
Comparison of ³H-spiperone binding in caudate nuclei of rabbits and rats.	
HERNANDEZ, L. L. and D. A. POWELL	253
Effect of chronic nicotine treatment against repeated immobilization stress.	
YAMANAKA, K., I. MURAMATSU and S. KIGOSHI	259
Dopaminergic and α_1-adrenergic properties of B-HT920 revealed in morphine-dependent rats.	
VAN DER LAAN, J. W.	265

Alterations in catecholamine levels and turnover in discrete brain areas after food deprivation.	
JHANWAR-UNIYAL, M., M. DARWISH, B. E. LEVIN and S. F. LEIBOWITZ	271
Hypophysectomy prevents ACTH-induced yawning and penile erection in rats.	
SERRA, G., W. FRATTA, M. COLLU and G. L. GESSA	277
Quantitative assessment of tolerance development to diisopropylfluorophosphate.	
LIM, D.-K., J. C. R. FERNANDO, B. HOSKINS and I. K. HO	281
Potentiated 5-hydroxytryptophan induced response suppression in rats following chronic reserpine.	
BRUGGE, K. L., J. N. HINGTGEN and M. H. APRISON	287
Zinc deficiency: Its role in gastric secretion and stress-induced gastric ulceration in rats.	
CHO, C. H., L. Y. Y. FONG, P. C. C. MA and C. W. OGLE	293
Electrophysiological correlates of stereotyped sniffing in rats injected with apomorphine.	
VANDERWOLF, C. H. and H. SZECHTMAN	299
Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions.	
FREEMAN, G. B., K. A. SHERMAN and G. E. GIBSON	305
Effects of age on antidepressant kinetics and memory in Fischer 344 rats.	
McMAHON, T. F., M. WEINER, L. LESKO and T. EMM	313
Assessment of the effects of phenylpropanolamine on appetite and food intake.	
CAFFRY, E. W., H. R. KISSILEFF and J. C. THORNTON	321
Pilocarpine-induced reciprocal hindlimb scratching in mice.	
SCOTT, R. W., T. L. GOODE and R. B. RAFFA	327
Effect of the 5HT₂ antagonist ritanserin on food intake and on 5HT-induced anorexia in the rat.	
MASSI, M. and S. MARINI	333
Role of polyamines in experience-dependent brain plasticity.	
FERCHMIN, P. A. and V. A. ETEROVIĆ	341
The role of brain catecholamines in the exhibition of muricide induced by nucleus accumbens lesions and the effect of antidepressants in rats.	
AL-KHATIB, Iz. M. H., M. FUJIWARA, K. IWASAKI, Y. KATAOKA and S. UEKI	351
Hippocampal electrical activity in relation to behavior following ethylcholine aziridinium ion (AF64A) treatment.	
STEWART, D. J., S. M. LEVENTER, I. HANIN and C. H. VANDERWOLF	357
Neurochemical and behavioral effects of N-ethyl-acetylcholine aziridinium chloride in mice.	
POPE, C. N., B. T. HO and A. A. WRIGHT	365
Hypothermia: Role of α_1- and α_2-noradrenergic receptors in the hypothalamus of the cat.	
MYERS, R. D., D. B. BELESLIN and A. H. REZVANI	373
Coincidence of seizure susceptibility to caffeine and to the benzodiazepine inverse agonist, DMCM, in SWR and CBA inbred mice.	
SEALE, T. W., J. M. CARNEY, O. M. RENNERT, M. FLUX and P. SKOLNICK	381

VOLUME INDEX

Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
MURPHY, J. M., W. J. McBRIDE, L. LUMENG and T.-K. LI 389

Nicotinic cholinergic influences on sexual receptivity in female rats.
WEAVER, D. R. and L. G. CLEMENS 393

Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys.
THOMPSON, D. M., P. J. WINSAUER and J. MASTROPAOLO 401

Studies on the central action of L-threo-3,4-dihydroxyphenyl-serine (L-threo-DOPS) in FLA-63-treated mice.
KATO, T., M. KATSUYAMA, N. KARAI, M. NAKAMURA and J. KATSUBE 407

Brief Communications

Amfonelic acid: Similarity to other dopamine agonists.
SCHECHTER, M. D. 413

Reduced anti-immobility effect of repeated desipramine (DMI) treatment in adult rats undernourished at perinatal age.
MOLINA, V. A., E. A. KELLER and O. A. ORSINGHER 417

Behavioral effects of intrahippocampal injections of clonidine, yohimbine and salbutamol in the rat.
VERLEYE, M. and F. BERNET 421

The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice.
GLENNON, R. A., P. J. LITTLE, J. A. ROSECRANS and M. YOUSIF 425

Differential biochemical mechanisms mediate locomotor stimulation effects by caffeine and nicotine in rats.
LEE, E. H. Y., M. J. TSAI, Y. P. TANG and C. Y. CHAI 427

Effect of acute administration of bromocriptine on isoproterenol- and angiotensin II-induced water intake in estrogen-treated rats.
FREGLY, M. J. 431

Meeting Report

Symposium on Neurobiology of Pain and Drug Abuse 435

The nociceptive jaw-opening reflex: Evidence for alpha₂ adrenoceptor involvement.
CURTIS, A. L. and J. MARWAH 437

Monoamine and opioid interactions in spinal analgesia and tolerance.
LOOMIS, C. W., K. JHAMANDAS, B. MILNE and F. CERVENKO 445

Cocaine modulation of central monoaminergic neurotransmission.
PITTS, D. K. and J. MARWAH 453

GABAergic mechanisms of analgesia: An update.
SAWYNOK, J. 463

CONTENTS

Editorial v

Articles

Influence of atropine and N-methyl atropine pretreatments on behavioral and physiological effects of the irreversible muscarinic agonist, BM123.
 OVERSTREET, D. H., R. W. RUSSELL, R. A. BOOTH and D. J. JENDEN 475

Interactions between sucrose, pain and isolation distress.
 BLASS, E., E. FITZGERALD and P. KEHOE 483

Exaggerated peripheral responses to catecholamines contributes to stress-induced hyperglycemia in the ob/ob mouse.
 KUHN, C. M., C. COCHRANE, M. N. FEINGLOS and R. S. SURWIT 491

The pyrazoloquinoline, CGS 8216, reduces sham feeding in the rat.
 KIRKHAM, T. C. and S. J. COOPER 497

Monosodium glutamate does not alter ACTH- or apomorphine-induced penile erection and yawning.
 ARGIOLAS, A., M. R. MELIS, W. FRATTA, A. MAURI and G. L. GESSA .. 503

The actions of SCH 23390, a D1 receptor antagonist, on operant and avoidance behavior in rats.
 SANGER, D. J. 509

Effects of naloxone and naltrexone on meal patterns of freely-feeding rats.
 KIRKHAM, T. C. and J. E. BLUNDELL 515

Benzodiazepine self-administration in rhesus monkeys: Estazolam, flurazepam and lorazepam.
 JOHANSON, C. E. 521

Amphetamine-elicited perseverative and rotational behavior: Evaluation of directional preference.
 KOKKINIDIS, L. 527

Acute Δ^9 -tetrahydrocannabinol exposure: Effects on hypothalamic-pituitary-testicular activity in mice.
 DALTERIO, S., R. STEGER, J. PELUSO and L. DE PAOLO 533

Short-term and delayed behavioral effects of pre- and post-weaning morphine in mice.
 ALLEVA, E. and G. LAVIOLA 539

The effect of neurotransmitters on cataleptic behavior induced by PG D₂ in rats.
 SAITO, R., M. FUJIWARA, H. KAMIYA and N. ONO 543

Methcathinone: A new and potent amphetamine-like agent.
 GLENNON, R. A., M. YOUSIF, N. NAIMAN and P. KALIX 547

Potential of odor by taste and odor aversions in rats are regulated by cholinergic activity of dorsal hippocampus.	
BERMÚDEZ-RATTONI, F., K. L. COBURN, J. FERNÁNDEZ, A. F. CHÁVEZ and J. GARCIA	553
Chlordiazepoxide and stress tolerance in rats.	
HENKE, P. G.	561
Seasonal difference in thermoregulatory responses to opiates in a mammalian hibernator.	
WANG, L. C. H., T. F. LEE and M. L. JOURDAN	565
A comparison of cocaine and its metabolite norcocaine: Effects on locomotor activity.	
ELLIOTT, P. J., G. M. ROSEN and C. B. NEMEROFF	573
Maternal aggression towards different sized male opponents: Effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders.	
MOS, J., B. OLIVIER and R. VAN OORSCHOT	577
Sham feeding of sucrose increases the ratio of 3,4-dihydroxyphenylacetic acid to dopamine in the hypothalamus.	
SMITH, G. P., K. A. BOURBONAIS, C. JEROME and K. J. SIMANSKY	585
Differential effects of nialamide and clomipramine on serotonin efflux and autoreceptors.	
OFFORD, S. J. and R. O. WARWICK, JR.	593
Lack of tolerance or withdrawal effects in mice after chronic administration of the non-sedating anxiolytic, CGS 9896.	
BOAST, C. A. and S. C. GERHARDT	601
Effects of 5,7-dihydroxytryptamine lesions of the nucleus accumbens on rat intravenous morphine self-administration.	
SMITH, J. E., K. SHULTZ, C. CO, N. E. GOEDERS and S. I. DWORKIN ..	607
Alterations in brain catecholamines during pregnancy.	
SMOLEN, A., T. N. SMOLEN and J. L. VAN DE KAMP	613
Atropine sulfate increases pituitary responses to stress.	
KANT, G. J., L. LANDMAN-ROBERTS, T. EGGLESTON and J. L. MEYERHOFF	619
A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.	
BRUFANI, M., C. CASTELLANO, M. MARTA, A. OLIVERIO, P. G. PAGELLA, F. PAVONE, M. POMPONI and P. L. RUGARLI	625
The effect of chlordiazepoxide on the habituation of exploration: Interactions with the benzodiazepine antagonist RO 15-1788.	
LISTER, R. G. and S. E. FILE	631
Brief Communications	
Prevention of fluphenazine-induced changes in dopaminergic and muscarinic receptors by lithium.	
GIANUTSOS, G. and E. FRIEDMAN	635
Studies of thyrotropin-releasing hormone (TRH)-induced defecation in cats.	
BELESLIN, D. B., D. JOVANOVIĆ-MICIĆ, R. SAMARDZIĆ and B. TERZIĆ	639
Changes in motor activities induced by microinjections of the selective dopamine agonists LY 171555, quinpirole hydrochloride, and SK&F 38393 into the habenula nucleus.	
THORNTON, E. W., J. A. C. EVANS and A. WICKENS	643

CONTENTS

Editorial v

Articles

Effects of pentobarbital and flurazepam on respiratory neurons in undrugged cats.
 DENAVIT-SAUBIÉ, M., A. S. FOUTZ, M.-P. MORIN-SURUN, E. BOUDINOT,
 J. CHAMPAGNAT and S. F. GONSALVES 647

Variations of norepinephrine concentrations following chronic stressor application.
 ANISMAN, H., J. IRWIN, W. BOWERS, P. AHLUWALIA and
 R. M. ZACHARKO 653

A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
 FREY, J. M., W. W. MORGAN, M. K. TICKU and R. D. HUFFMAN 661

Doubtful role for phencyclidine metabolites in PCP enhancement of QNB binding.
 BOGGAN, W. O. and L. D. MIDDAUGH 671

The differential effects of naloxone hydrochloride on the acquisition and maintenance of
 schedule-induced polydipsia.
 RILEY, A. L. and C. L. WETHERINGTON 677

Effects of centrally administered H2 antagonists on motor activity.
 O'NEILL, K. A. and S. B. GERTNER 683

Effects of the dopamine D-1 antagonist SCH 23390 and the D-2 antagonist sulpiride on saline acceptance-
 rejection in water-deprived rats.
 GILBERT, D. B. and S. J. COOPER 687

Effects of chronic ethanol exposure on adenylate cyclase activities in the rat.
 RABIN, R. A., R. C. BAKER and R. A. DEITRICH 693

The effects of ICV-CRH on novelty-induced behavior.
 SHERMAN, J. E. and N. H. KALIN 699

Delineation of mu-antagonist, partial kappa agonist and non-opioid agonist activity of cyclazocine using
 urinary output of rats.
 LEANDER, J. D. 705

The direct enhancement of positive palatability by chlordiazepoxide is antagonized by Ro 15-1788
 and CGS 8216.
 TREIT, D., K. C. BERRIDGE and C. E. SCHULTZ 709

SCH 23390 and its S-enantiomer stereoselectively prevent EEG and behavioral activation induced by
 dopamine agonists in the rabbit.
 ONGINI, E., M. G. CAPORALI, M. MASSOTTI and S. SAGRATELLA 715

Increased sensitivity to the stimulus properties of morphine in food deprived rats.
 GAIARDI, M., M. BARTOLETTI, A. BACCHI, C. GUBELLINI and M. BABBINI 719

Changes of brain monoamine contents in three models of experimentally induced muricide in rats. TANI, Y., Y. KATAOKA, Y. SAKURAI, K. YAMASHITA, M. USHIO and S. UEKI	725
Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation. GALLISTEL, C. R. and G. FREYD	731
Opioid-induced linear running in obese (<i>ob/ob</i>) and lean mice. CALCAGNETTI, D. J., J. J. FLYNN and D. L. MARGULES	743
Harman induces preference for ethanol in rats: Is the effect specific for ethanol? ROMMELSPACHER, H., C. BÜCHAU and J. WEISS	749
Food intake of domestic fowl injected with adrenergic agonists and antagonists into the hepatic portal vein. HOWES, G. A. and J. M. FORBES	757
Nucleus accumbens opiate-dopamine interactions and locomotor activation in the rat: Evidence for a pre-synaptic locus. SWERDLOW, N. R., M. AMALRIC and G. F. KOOB	765
Cholinergic stimulation of drinking from the lateral hypothalamus: Indications for M₂ muscarinic receptor mediation. HAGAN, J. J., J. A. D. M. TONNAER and C. L. E. BROEKKAMP	771
Naloxone inhibits mating and conditioned place preference for an estrous female in male rats soon after castration. MILLER, R. L. and M. J. BAUM	781
Clonidine and prazosin block the iminodipropionitrile (IDPN)-induced spasmodic dyskinetic syndrome in mice. CADET, J. L., T. BRAUN and W. J. FREED	791
Development of physical dependence on midazolam by oral self-administration. FALK, J. L. and M. TANG	797
Interactions of diazepam and caffeine: Behavioral and subjective dose effects in humans. ROACHE, J. D. and R. R. GRIFFITHS	801
Sex differences in the recovery of brain acetylcholinesterase activity following a single exposure to DFP. SMOLEN, A., T. N. SMOLEN, P. C. HAN and A. C. COLLINS	813
Long-lasting effects of escalating doses of <i>d</i>-amphetamine on brain monoamines, amphetamine-induced stereotyped behavior and spontaneous nocturnal locomotion. ROBINSON, T. E. and D. M. CAMP	821
Brief Communications	
Effects of stress on [³H]cyclohexyladenosine binding to rat brain membranes. ANDERSON, S. M., J. R. LEU and G. J. KANT	829
Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. WOOLVERTON, W. L.	835
Behavioral effects resulting from sub-chronic treatment of rats with extract of fresh stabilized cola seeds. SCOTTO, G., C. MAILLARD, J. VION-DURY, G. BALANSARD and G. JADOT	841

VOLUME INDEX

Effect of phencyclidine and two monohydroxy metabolites on ³H QNB binding <i>in vivo</i> in rats.	
BOGGAN, W. O., A. J. STRINGER, K. FAUGHT and L. D. MIDDAUGH	... 847
Altered splenic catecholamine concentrations during experimental allergic encephalomyelitis.	
WESSELMANN, U., R. J. KONKOL, G. L. LEO, D. L. ROERIG and D. R. HARDER 851

SUBJECT INDEX

- Acetylcholinesterase. 625
 cholinesterase inhibitors
 heptyl
 locomotor activity
 memory
 physostigmine analogues
 Acetylcholinesterase activity. 813
 choline acetyltransferase activity
 diisopropylphosphorofluoridate
 muscarinic receptors
 nicotinic receptors
 recovery
 sex differences
 Acetylcholinesterase inhibition. 119
 formetanate
 operant behavior
 schedule-controlled responding
 ACh formation. 305
 DOPAC/DA ratio
 dose-dependent effects
 locomotor activity
 neurochemical actions
 nicotine
 time-dependent effects
 Acquisition and maintenance. 677
 drinking
 naloxone
 schedule-induced polydipsia
 Acute administration
 alcohol. 29
 analgesia. 153
 angiotensin II. 431
 antidepressants. 153
 antidipsogenic effect. 431
 behavioral impairment. 29
 bromocriptine. 431
 CGS 9896. 601
 chronic administration. 153, 593, 601
 clomipramine. 593
 diazepam. 601
 differential effects. 593
 diisopropylfluorophosphate. 281
 drinking. 431
 drug comparisons. 601
 drug interaction. 153
 endogenous opioid system. 153
 beta-endorphin concentrations. 153
 estrogen pretreatment. 431
 5-HT autoreceptors. 593
 human studies, males. 29
 isoproterenol. 431
 learning. 29
 nialamide. 593
 serotonin efflux. 593
 serotonergic system. 153
 subacute administration. 281
 tolerance. 29, 601
 tolerance development. 281
 withdrawal effects. 601
 Acute exposure. 533
 clonidine
 hypothalamus
 in vitro
 in vivo
 testes
 testosterone
 Δ^9 -tetrahydrocannabinol
 Adaptation. 141
 behavioral effects
 environmental familiarity
 prior drug experience
 delta-9-tetrahydrocannabinol
 Additive effects. 427
 amino acid precursors
 caffeine
 catecholamine release
 drug interactions
 locomotor activity
 nicotine
 Adenylate cyclase. 693
 chronic administration
 ethanol
 in vitro
 liquid diet
 tolerance
 Adrenergic agonists. 757
 adrenergic antagonists
 chickens
 dose-response relationship
 epinephrine
 food intake
 hepatic portal vein
 vagotomy
 beta-Adrenergic agonists. 11
 β_1 receptors
 β_2 receptors
 betaxolol
 chronic administration
 clenbuterol
 IPS-339
 spontaneous motor activity
 Adrenergic antagonists. 757
 adrenergic agonists
 chickens
 dose-response relationship
 epinephrine
 food intake
 hepatic portal vein
 vagotomy
 α_1 -Adrenergic properties. 265
 B-HT920
 dopaminergic properties
 morphine-withdrawal behavior
 α -Adrenoceptors. 791
 clonidine
 iminodipropionitrile
 prazosin
 spasmodic syndrome, drug induced
 α_2 -Adrenoceptors
 β -adrenoceptors. 259
 chronic administration. 259
 clonidine. 437
 immobilization stress. 259
 jaw opening reflex. 437
 muscarinic cholinceptors. 259
 nicotine. 259
 nociception. 437
 rabbit/rat comparisons. 437
 stress, repeated. 259
 β -Adrenoceptors. 259
 α_2 -adrenoceptors
 chronic administration
 immobilization stress
 muscarinic cholinceptors
 nicotine
 stress, repeated
 Adrenocorticotrophic hormone
 apomorphine. 503
 hypophysectomy. 277, 503
 monosodium glutamate. 503
 penile erection. 277, 503
 yawning. 277, 503
 Age differences
 aggression, shock-induced. 83
 antidepressants. 313
 co-dergocrine. 95
 GABA levels, brain. 83
 inbred mice. 83
 kinetics. 313
 learning and memory. 95
 local cerebral glucose utilization. 95
 locus ceruleus. 95
 maze performance. 95
 memory, short-term. 313
 strain differences. 83
 Aggression. 229
 brain transmitters
 dose related effects
 footshock aggression
 propranolol
 Aggression, drug induced. 217
 amygdala
 locomotor activity
 norepinephrine
 Aggression, shocked-induced. 83
 age differences
 GABA levels, brain
 inbred mice
 strain differences
 Alcohol
 acute administration. 29
 alcohol preference. 749
 behavioral impairment. 29
 β -carbolines. 749
 drug comparisons. 749
 harmalan. 749
 human studies, males. 29
 learning. 29
 tolerance. 29
 ultradian rhythm. 749
 Alcohol nonpreferring rats. 389
 alcohol preferring rats
 forebrain
 monoamine content
 strain differences
 Alcohol preference. 749
 alcohol
 β -carbolines
 drug comparisons
 harmalan
 ultradian rhythm
 Alcohol preferring rats. 389
 alcohol nonpreferring rats
 forebrain
 monoamine content
 strain differences
 Alkali metals. 235
 in vitro

- in vivo
- lithium
 - mechanism of action
 - superoxide dismutase
- Amfonelic acid, 413
 - dopamine agonists
 - drug discrimination
- Amino acid precursors, 427
 - additive effects
 - caffeine
 - catecholamine release
 - drug interactions
 - locomotor activity
 - nicotine
- Amphetamine, 167
 - drug interaction
 - fixed-interval schedule
 - fixed-ratio schedule
 - naloxone
- d-Amphetamine
 - brain monoamines, 821
 - chlordiazepoxide, 577
 - directional behavior, 527
 - dopamine, 821
 - dose differences, 821
 - footshock, 17
 - habituation, 7
 - intruder treatment, 577
 - locomotor activity, nocturnal, 821
 - long-lasting effects, 821
 - maternal aggression, 577
 - maternal treatment, 577
 - opponent size, 577
 - perseveration, 527
 - rearing, off-wall, 7
 - rearing, on-wall, 7
 - rotational behavior, 17, 527
 - rotational bias, 17
 - serotonin, 821
 - sex differences, 17
 - spontaneous alternation, 527
 - stereotyped behavior, 821
- Amygdala
 - aggression, drug induced, 217
 - convulsions, drug induced, 159
 - kindling, 159
 - locomotor activity, 217
 - norepinephrine, 217
 - olfactory bulb, 159
 - pentylentetrazol, 159
 - seizures, 159
 - sensitization, 159
- Analgesia
 - acute administration, 153
 - antidepressants, 153
 - chronic administration, 153
 - corticotropin-releasing hormone, 699
 - drug interaction, 153
 - endogenous opioid system, 153
 - beta-endorphin concentrations, 153
 - GABA agonists, 463
 - GABA-transaminase inhibitors, 463
 - locomotor activity, 539
 - morphine, 539
 - noradrenergic pathways, 463
 - novelty-induced behavior, 699
 - post-weaning exposure, 539
 - pre-weaning exposure, 539
 - serotonergic system, 153
- Analgesic effect, 57
 - β -endorphin
 - oxytocin
- tolerance
- Angiotensin II, 431
 - acute administration
 - antidipsogenic effect
 - bromocriptine
 - drinking
 - estrogen pretreatment
 - isoproterenol
- Anorexia, 5-HT induced, 333
 - eating
 - 5-hydroxytryptamine
 - ritanserin
- Antidepressants
 - acute administration, 153
 - age differences, 313
 - analgesia, 153
 - benzodiazepine receptors, 35
 - catecholamines, 351
 - chronic administration, 153
 - DOPAC, 351
 - dopamine, 351
 - drug comparisons, 351
 - drug interaction, 153
 - endogenous opioid system, 153
 - beta-endorphin concentrations, 153
 - [³H]flunitrazepam binding sites, 35
 - kinetics, 313
 - lesions, nucleus accumbens, 351
 - memory, short-term, 313
 - muricide, 351
 - nucleus accumbens, 351
 - route of administration, 35
 - serotonergic system, 153
- Antidipsogenic effect, 431
 - acute administration
 - angiotensin II
 - bromocriptine
 - drinking
 - estrogen pretreatment
 - isoproterenol
- Anti-immobility effect, 417
 - chronic administration
 - desipramine
 - perinatal undernutrition
- Antinociception
 - continuous infusion, 131
 - cross tolerance, 131
 - lesions, electrolytic, 187
 - muscimol, 187
 - self-injurious behavior, 187
 - spinal cord, 131
 - stereotyped behavior, 187
 - substantia nigra, 187
 - superior colliculus, 187
 - ventromedial thalamus, 187
- Anxiolytic drugs, 111
 - corridor-type runway
 - drug screening
- Apomorphine
 - adrenocorticotrophic hormone, 503
 - electrophysiological correlates, 299
 - hypophysectomy, 503
 - monosodium glutamate, 503
 - penile erection, 503
 - sniffing, 299
 - stereotyped behavior, 299
 - yawning, 503
- Apparatus
 - corridor-type runway, 111
 - gastric fistulas, 497
 - holeboard, 631, 643
 - macroelectrodes, 299
- mini-osmotic pumps, 131
- radial arm maze, 1, 365
- radial maze, 23
- rotometer, 17
- shuttlebox, 17, 509
- Y-maze, 527
- Appetite, 321
 - eating
 - food intake
 - human studies, females
 - phenylpropranolamine
- Anterior hypothalamus/preoptic area, 373
 - cats
 - hypothermia
 - α -noradrenergic receptors
 - thermoregulation
- Atropine, 475
 - BM123
 - drug interaction
 - muscarinic receptor
 - N-methyl atropine
 - reversible association
- Atropine sulfate, 619
 - cyclic AMP
 - footshock
 - immobilization
 - methylatropine nitrate
 - pituitary
 - prolactin
 - stress
- Attack targets, 61
 - defensive behavior
 - ethanol
 - group formation
 - offensive behavior
 - social/agonistic interactions
- Autoreceptor blockade, 223
 - dopamine receptor hypersensitivity
 - neuroleptics
- Avoidance, 509
 - D1 receptors
 - operant responding
 - SCH 23390
- Avoidance performance, 241
 - haloperidol
 - latent inhibition
- Behavioral activation, 715
 - benzazepine enantiomers
 - dopamine agonists
 - drug comparisons
 - EEG activation
 - rabbits
 - SCH 23388
 - SCH 23390
- Behavioral effects
 - adaptation, 141
 - caffeine, 801, 841
 - clonidine, 421
 - cola seeds, 841
 - diazepam, 801
 - dose effects, 801
 - drug comparisons, 841
 - drug interactions, 801
 - electrical activity, 357
 - environmental familiarity, 141
 - ethylcholine aziridinium ion, 357
 - hippocampus, 357, 421
 - human studies, males, 801
 - intrahippocampal administration, 421
 - prior drug experience, 141

- psychostimulants, 841
- rhythmical slow activity, 357
- salbutamol, 421
- sub-chronic treatment, 841
- Δ^9 -tetrahydrocannabinol, 141
- yohimbine, 421
- Behavioral impairment, 29**
 - acute administration
 - alcohol
 - human studies, males
 - learning
 - tolerance
- Behavioral-potency comparison, 425**
 - N-methyl-1-(3,4-methylene-dioxyphenyl)-2-aminopropane
 - phenylisopropylamines
 - schedule-controlled responding
- Benserazide, 407**
 - L-threo-3,4-dihydroxyphenylserine
 - FLA-63
 - locomotor activity
 - nialamide
 - norepinephrine levels
- Benzodiazepine antagonists, 631**
 - chlordiazepoxide
 - drug interactions
 - exploration
 - habituation
 - locomotor activity
 - RO 15-1788
- Benzazepine enantiomers, 715**
 - behavioral activation
 - dopamine agonists
 - drug comparisons
 - EEG activation
 - rabbits
 - SCH 23388
 - SCH 23390
- Benzodiazepine receptor ligands, 247**
 - differential effects
 - drinking
 - isotonic saline consumption
 - rats, males
 - water consumption
- Benzodiazepine receptors**
 - antidepressants, 35
 - CGS 8216, 497
 - [³H]flunitrazepam binding sites, 35
 - palatability, 497
 - route of administration, 35
 - sham feeding, 497
- Benzodiazepines, 521**
 - monkeys
 - self-administration
- β_1 receptors, 11**
 - beta-adrenergic agonists
 - β_2 receptors
 - betaxolol
 - chronic administration
 - clenbuterol
 - IPS-339
 - spontaneous motor activity
- β_2 receptors, 11**
 - beta-adrenergic agonists
 - β_1 receptors
 - betaxolol
 - chronic administration
 - clenbuterol
 - IPS-339
 - spontaneous motor activity
- Betaxolol, 11**
 - beta-adrenergic agonists
- β_1 receptors**
- β_2 receptors**
- chronic administration
- clenbuterol
- IPS-339
- spontaneous motor activity
- B-HT920, 265**
 - α_1 -adrenergic properties
 - dopaminergic properties
 - morphine-withdrawal behavior
- Biogenic amines, 725**
 - lesions, midbrain raphe nucleus
 - lesions, nucleus accumbens
 - monoamine content
 - muricide
 - olfactory bulbectomy
- Biphasic effects, 65**
 - dose-response
 - locomotor activity
 - toluene inhalation
- Blood glucose responses, 491**
 - hyperglycemia, stress-induced
 - plasma insulin responses
 - sympathetic nervous system
- BM123, 475**
 - atropine
 - drug interaction
 - muscarinic receptor
 - N-methyl atropine
 - reversible association
- Body weight gain, 293**
 - gastric secretion
 - gastric ulceration
 - mast cells
 - stress
 - zinc deficiency
- Brain**
 - anterior caudate nucleus, 607
 - anterior globus pallidus, 49
 - anterior hypothalamic nucleus, 271
 - anterior hypothalamus/preoptic area, 373
 - anterior striatum, 389
 - amygdala, 83, 159, 217, 585
 - basal ganglia, 49, 661
 - basolateral amygdala, 351, 725
 - CA3 of the hippocampus, 357
 - caudate nucleus, 253, 271
 - caudate-putamen, 95
 - Central amygdala, 351, 725
 - cerebellum, 83, 693, 847
 - cerebral cortex, 203, 259
 - corpus callosum, 357
 - cortex, 173, 305, 613, 653, 813, 847
 - dorsal hippocampus, 299
 - dorsal raphe nucleus, 453
 - dorsomedial nucleus, 271
 - entopeduncular nucleus, 49
 - fimbria-formix, 357
 - frontal cortex, 95, 351, 389, 725, 829
 - fronto-parietal cortex, 553
 - globus pallidus, 49, 95
 - habenula nucleus, 643
 - hindbrain, 813
 - hippocampus, 95, 259, 357, 365, 421, 553, 613, 635, 653, 813, 829, 847
 - hypothalamus, 49, 173, 271, 333, 373, 533, 585, 653, 813, 829, 847
 - inferotemporal cortex, 89
 - internal capsule, 95
 - lateral hypothalamus, 351, 725, 771
 - locus ceruleus, 95, 453
 - mamillary body, 725
 - medial amygdala, 725
 - medial forebrain bundle, 731
 - medial frontal cortex, 821
 - median eminence, 533
 - median raphe nucleus, 95
 - medulla, 647
 - midbrain, 173, 613, 813
 - neocortex, 299, 357
 - nucleus accumbens, 49, 351, 389, 585, 607, 765, 821
 - olfactory bulb, 159, 299
 - parahippocampal cortex, 365
 - paraventricular nucleus, 271, 333
 - perifornical lateral hypothalamus, 271
 - pituitary, 533, 619
 - pons-medulla, 173
 - prefrontal cortex, 89
 - Purkinje neurons, 453
 - pyriform cortex, 585, 607
 - raphe nuclei, 83
 - rostral caudate putamen, 351
 - striatum, 49, 83, 173, 305, 357, 365, 613, 635, 693, 813, 821, 829, 847
 - subiculum, 95
 - substantia nigra, 83, 187
 - subthalamic nucleus, 49
 - superior colliculus, 187
 - thalamic ventromedial nucleus, 49
 - ventral globus pallidus, 49
 - ventral tegmental area, 453
 - ventromedial hypothalamus, 725
 - ventromedial thalamus, 49, 187
 - zona compacta, 453
- Brain catecholamines, 613**
 - catecholamine turnover
 - dopamine
 - norepinephrine
 - pregnancy
 - seizure susceptibility
- Brain monoamines, 821**
 - d*-amphetamine
 - dopamine dose differences
 - locomotor activity, nocturnal
 - long-lasting effects
 - serotonin
 - stereotyped behavior
- Brain plasticity, experience dependent, 341**
 - difluoromethylornithine
 - environmental complexity
 - environmental impoverishment
 - polyamines
- Brain transmitters, 229**
 - aggression
 - dose related effects
 - footshock aggression
 - propranolol
- Bromocriptine, 431**
 - acute administration
 - angiotensin II
 - antidipsogenic effect
 - drinking
 - estrogen pretreatment
 - isoproterenol
- Caffeine**
 - additive effects, 427
 - amino acid precursors, 427
 - behavioral effects, 801, 841
 - catecholamine release, 427

- cola seeds, 841
- diazepam, 801
- dose effects, 801
- drug comparisons, 841
- drug interactions, 427, 801
- human studies, males, 801
- inbred strains, 381
- locomotor activity, 427
- methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate, 381
- nicotine, 427
- picrotoxinin, 381
- psychostimulants, 841
- Ro 5-4864, 381
- seizure susceptibility, 381
- sub-chronic treatment, 841
- β -Carbolines, 749
 - alcohol
 - alcohol preference
 - drug comparisons
 - harmalan
 - ultradian rhythm
- Castration, 781
 - conditioned place preference
 - estrous
 - mating behavior
 - naloxone
 - sexual reward
- Catalepsy, 45
 - locomotor activity, backward walking
 - morphine
 - RU 24213
 - SKF 38393
- Cataleptic behavior, 543
 - cholinergic system
 - dopaminergic system
 - prostaglandin D₂
 - serotonergic system
- Catecholamine concentrations, 851
 - experimental allergic encephalomyelitis
 - spleen
- Catecholamine levels, 271
 - catecholamine turnover
 - food deprivation
 - hypothalamus
 - α -methyl-p-tyrosine
- Catecholamine release, 427
 - additive effects
 - amino acid precursors
 - caffeine
 - drug interactions
 - locomotor activity
 - nicotine
- Catecholamine turnover
 - brain catecholamines, 613
 - catecholamine levels, 271
 - dopamine, 613
 - food deprivation, 271
 - hypothalamus, 271
 - α -methyl-p-tyrosine, 271
 - norepinephrine, 613
 - pregnancy, 613
 - seizure susceptibility, 613
- Catecholamines, 351
 - antidepressants
 - DOPAC
 - dopamine
 - drug comparisons
 - lesions, nucleus accumbens
 - muricide
 - nucleus accumbens
 - positive palatability, 709
 - restraint stress, 561
 - Ro 15-1788, 631, 709
 - stress tolerance, 561
 - ulcers, 561
- Catecholaminergic agonists, 731
 - catecholaminergic antagonists
 - drug comparisons
 - electrical brain stimulation
 - quantitative determination
 - rewarding efficacy
- Catecholaminergic antagonists, 731
 - catecholaminergic agonists
 - drug comparisons
 - electrical brain stimulation
 - quantitative determination
 - rewarding efficacy
- Cats
 - anterior hypothalamus/preoptic area, 373
 - defecation, 639
 - flurazepam, 647
 - hypothermia, 373
 - α -noradrenergic receptors, 373
 - pentobarbital, 647
 - respiration, 647
 - respiratory neurons, 647
 - thermoregulation, 373
 - thyrotropin-releasing-hormone, 639
- Caudate nucleus, 253
 - dopamine receptors
 - rabbit/rat comparisons
 - ³H-spiperone
 - ³H-spiperone binding
- CGS 8216
 - benzodiazepine receptors, 497
 - chlordiazepoxide, 709
 - differential effects, 145
 - direct enhancement, 709
 - drinking, 145
 - drug interactions, 709
 - eating, 145
 - food deprivation, 145
 - naltrexone, 145
 - palatability, 497
 - positive palatability, 709
 - Ro 15-1788, 709
 - sham feeding, 497
 - water deprivation, 145
- CGS 9896, 601
 - acute administration
 - chronic administration
 - diazepam
 - drug comparisons
 - tolerance
 - withdrawal effects
- Chickens, 757
 - adrenergic agonists
 - adrenergic antagonists
 - dose-response relationship
 - epinephrine
 - food intake
 - hepatic portal vein
 - vagotomy
- Chlordiazepoxide
 - d-amphetamine, 577
 - benzodiazepine antagonists, 631
 - CGS 8216, 709
 - direct enhancement, 709
 - drug interactions, 631, 709
 - exploration, 631
 - habituation, 631
 - intruder treatment, 577
 - locomotor activity, 631
 - maternal aggression, 577
 - maternal treatment, 577
 - opponent size, 577
- Chlorimipramine, 207
 - desipramine
 - hole board response
 - stress
 - stress-induced behavior
 - voluntary drug ingestion
- Choline acetyltransferase (ChAT) activity, 813
 - acetylcholinesterase activity
 - diisopropylphosphofluoridate
 - muscarinic receptors
 - nicotinic receptors
 - recovery
 - sex differences
- Choline uptake, 365
 - memory, reference
 - memory, working
 - N-ethyl-acetylcholine aziridinium
- Cholinergic activity, 553
 - hippocampus
 - odor aversions
 - taste aversions
- Cholinergic system, 543
 - cataleptic behavior
 - dopaminergic system
 - prostaglandin D₂
 - serotonergic system
- Cholinergic stimulation, 771
 - drinking
 - lateral hypothalamus
 - M₁ muscarinic receptors
 - M₂ muscarinic receptors
- Cholinesterase inhibition, 625
 - acetylcholinesterase
 - heptyl
 - locomotor activity
 - memory
 - physostigmine analogues
- Chronic administration
 - acute administration, 153, 593, 601
 - adenylate cyclase, 693
 - beta-adrenergic agonists, 11
 - α_2 -adrenoceptors, 259
 - β -adrenoceptors, 259
 - analgesia, 153
 - antidepressants, 153
 - anti-immobility effect, 417
 - β 1 receptors, 11
 - β 2 receptors, 11
 - betaxolol, 11
 - CGS 9896, 601
 - clenbuterol, 11
 - clomipramine, 593
 - cognitive effects, 1
 - [³H]DADLE binding, 203
 - desipramine, 417
 - diazepam, 601
 - differential effects, 593
 - dopamine receptor binding, 635
 - down-regulation, 635
 - drug comparisons, 601
 - drug interaction, 153
 - electroconvulsive shock treatment, 203
 - endogenous opioid system, 153
 - beta-endorphin concentrations, 153
 - ethanol, 693
 - fluphenazine, 635

- haloperidol, 1
- 5-HT autoreceptors, 593
- 6-hydroxydopamine, 203
- imipramine, 203
- immobilization stress, 259
- in vitro, 693
- IPS-339, 11
- liquid diet, 693
- lithium, 635
- monkeys, 191
- motor effects, 1
- muscarinic cholinceptors, 259
- muscarinic receptor binding, 635
- naloxone, 191
- nialamide, 593
- nicotine, 259
- opioid δ receptor, 203
- oral movements, 1
- perinatal undernutrition, 417
- rate of responding, 191
- reserpine, 203
- serotonin efflux, 593
- serotonergic system, 153
- shock titration, 191
- spontaneous motor activity, 11
- stress, repeated, 259
- tolerance, 601, 693
- withdrawal effects, 601
- Chronic treatment, 287
 - depression, drug induced
 - reserpine
 - 5-HT receptors
 - 5-hydroxytryptophan
- Circannual rhythm, 565
 - hibernation
 - seasonal difference
 - squirrels
 - thermoregulation
- Clenbuterol, 11
 - beta-adrenergic agonists
 - β 1 receptors
 - β 2 receptors
 - betaxolol
 - chronic administration
 - IPS-339
 - spontaneous motor activity
- Clomipramine, 593
 - acute administration
 - chronic administration
 - differential effects
 - 5-HT autoreceptors
 - nialamide
 - serotonin efflux
- Clonidine
 - acute exposure, 533
 - alpha-adrenoceptors, 437, 791
 - behavioral effects, 421
 - hippocampus, 421
 - hypothalamus, 533
 - iminodipropionitrile, 791
 - intrahippocampal administration, 421
 - in vitro, 533
 - in vivo, 533
 - jaw opening reflex, 437
 - nociception, 437
 - prazosin, 791
 - rabbit/rat comparisons, 437
 - salbutamol, 421
 - spasmodic syndrome, drug-induced, 791
 - testes, 533
 - testosterone, 533
 - Δ^9 -tetrahydrocannabinol, 533
 - yohimbine, 421
- Cocaine
 - drug comparisons, 573
 - estrous cycle, 37
 - haloperidol, 37
 - in vivo, 453
 - locomotor activity, 573
 - monoaminergic neurotransmission, 453
 - neuroleptic activity, 37
 - norcocaine, 573
 - ovariectomy, 37
 - route of administration, 573
 - self-administration, 37
- Co-dergocrine, 95
 - age differences
 - learning and memory
 - local cerebral glucose utilization
 - locus ceruleus
 - maze performance
- Cognitive effects, 1
 - chronic administration
 - haloperidol
 - motor effects
 - oral movements
- Cola seeds, 841
 - behavioral effects
 - caffeine
 - drug comparisons
 - psychostimulants
 - sub-chronic treatment
- Concentration variations, 653
 - footshock
 - norepinephrine
 - stress, chronic
- Conditioned flavor aversion, 211
 - conditioned place preference
 - neonates
 - odor
 - reinforcement
 - stimulant drugs
- Conditioned place preference
 - castration, 781
 - conditioned flavor aversion, 211
 - estrous, 781
 - mating behavior, 781
 - naloxone, 781
 - neonates, 211
 - odor, 211
 - reinforcement, 211
 - sexual reward, 781
 - stimulant drugs, 211
- Continuous infusion, 131
 - antinociception
 - cross tolerance
 - spinal cord
- Convulsions, drug induced, 159
 - amygdala
 - kindling
 - olfactory, bulb
 - pentylentetrazol
 - seizures
 - sensitization
- Corridor-type runway, 111
 - anxiolytic drugs
 - drug screening
- Corticotropin-releasing hormone, 699
 - analgesia
 - novelty-induced behavior
- Cross tolerance
 - antinociception, 131
 - continuous infusion, 131
 - monoamine/opioid interactions, 445
 - muscarinic receptors, 173
 - naloxone, 445
 - organophosphates, 173
 - QNB binding, 173
 - spinal analgesia, 445
 - spinal cord, 131
 - strain differences, 173
 - tolerance, 173, 445
- Cyclazocine, 705
 - diuresis
 - kappa agonist, partial
 - mu-antagonist
 - non-opioid agonist
 - urinary output
- Cyclic AMP, 619
 - atropine sulfate
 - footshock
 - immobilization
 - methylatropine nitrate
 - pituitary
 - prolactin
 - stress
- [³H]Cyclohexyladenosine binding, 829
 - neuromodulator receptors
 - neurotransmitter receptors
 - stress, chronic
- D1 receptors, 509
 - avoidance
 - operant responding
 - SCH 23390
- [³H]DADLE binding, 203
 - chronic administration
 - electroconvulsive shock treatment
 - 6-hydroxydopamine
 - imipramine
 - opioid δ receptor
 - reserpine
- Defecation, 639
 - cats
 - thyrotropin-releasing hormone
- Defensive behavior, 61
 - attack targets
 - ethanol
 - group formation
 - offensive behavior
 - social/agonistic interactions
- Depression, drug induced, 287
 - chronic treatment
 - reserpine
 - 5-HT receptors
 - 5-hydroxytryptophan
- Desipramine
 - anti-immobility effect, 417
 - chlorimipramine, 207
 - chronic administration, 417
 - hole board response, 207
 - perinatal undernutrition, 417
 - stress, 207
 - stress-induced behavior, 207
 - voluntary drug ingestion, 207
- Diazepam
 - acute administration, 601
 - behavioral effects, 801
 - caffeine, 801
 - CGS 9896, 601
 - chronic administration, 601
 - dose effects, 801
 - drug comparisons, 601
 - drug interactions, 801

- human studies, males, 801
- tolerance, 601
- withdrawal effects, 601
- Differential effects
 - acute administration, 593
 - benzodiazepine receptor ligands, 247
 - CGS 8216, 145
 - chronic administration, 593
 - clomipramine, 593
 - drinking, 145, 247
 - eating, 145
 - food deprivation, 145
 - 5-HT autoreceptors, 593
 - isotonic saline consumption, 247
 - naltrexone, 145
 - nialamide, 593
 - rats, males, 247
 - serotonin efflux, 593
 - water consumption, 247
 - water deprivation, 145
- Difluoromethylornithine, 341
 - brain plasticity, experience dependent
 - environmental complexity
 - environmental impoverishment
 - polyamines
- Diisopropylphosphofluoridate
 - acetylcholinesterase activity, 813
 - acute administration, 281
 - choline acetyltransferase activity, 813
 - muscarinic receptors, 813
 - nicotinic receptors, 813
 - recovery, 813
 - sex differences, 813
 - subacute administration, 281
 - tolerance development, 281
- Direct enhancement, 709
 - CGS 8216
 - chlordiazepoxide
 - drug interactions
 - positive palatability
 - Ro 15-1788
- Directional behavior, 527
 - d-amphetamine
 - rotational behavior
 - perseveration
 - spontaneous alternation
- Discriminative properties, 719
 - food deprivation
 - morphine
 - reinforcing properties
- Diuresis, 705
 - cyclazocine
 - kappa agonist, partial
 - mu-antagonist
 - non-opioid agonist
 - urinary output
- DOPAC, 351
 - antidepressants
 - catecholamines
 - dopamine
 - drug comparisons
 - lesions, nucleus accumbens
 - muricide
 - nucleus accumbens
- DOPAC/DA ratio
 - ACh formation, 305
 - dose-dependent effects, 305
 - hypothalamus, 585
 - locomotor activity, 305
 - neurochemical actions, 305
 - nicotine, 305
 - sham feeding, 585
 - sucrose, 585
 - time-dependent effects, 305
- Dopamine
 - d-amphetamine, 821
 - antidepressants, 351
 - brain catecholamines, 613
 - brain monoamines, 821
 - catecholamines, 351
 - catecholamine turnover, 613
 - DOPAC, 351
 - dose differences, 821
 - drug comparisons, 351
 - drug interactions, 77, 765
 - lesions, nucleus accumbens, 351
 - locomotor activity, 765
 - locomotor activity, nocturnal, 821
 - long-lasting effects, 821
 - muricide, 351
 - muricide suppression, 77
 - nomifensine, 77
 - norepinephrine, 613
 - nucleus accumbens, 351, 765
 - opiates, 765
 - pregnancy, 613
 - pre-synaptic locus, 765
 - seizure susceptibility, 613
 - serotonin, 821
 - stereotyped behavior, 821
 - thiamine deficiency, 77
- Dopamine agonists
 - amfonelic acid, 413
 - behavioral activation, 715
 - benzazepine enantiomers, 715
 - drug comparisons, 715
 - drug discrimination, 413
 - EEG activation, 715
 - grooming, 643
 - habenula nucleus, 643
 - locomotor activity, 643
 - rabbits, 715
 - rearing, 643
 - SCH 23388, 715
 - SCH 23390, 715
- Dopamine antagonists, 123
 - dopamine autoreceptors
 - EEG slow wave activity
 - motor activity
 - sleep-wake activity
- Dopamine autoreceptors, 123
 - dopamine antagonists
 - EEG slow wave activity
 - motor activity
 - sleep-wake activity
- Dopamine D-1 receptors, 687
 - dopamine D-2 receptors
 - drinking
 - saline acceptance-rejection
 - SCH 23390
 - sulpiride
 - water deprivation
- Dopamine D-2 receptors, 687
 - dopamine D-1 receptors
 - drinking
 - saline acceptance-rejection
 - SCH 23390
 - sulpiride
 - water deprivation
- Dopamine receptor binding, 635
 - chronic administration
 - down-regulation
 - fluphenazine
 - lithium
 - muscarinic receptor binding
- Dopamine receptor hypersensitivity, 223
 - autoreceptor blockade
 - neuroleptics
- Dopamine receptors, 253
 - caudate nucleus
 - rabbit/rat comparisons
 - ³H-spiperone
 - ³H-spiperone binding
- Dopaminergic properties, 265
 - α_1 -adrenergic properties
 - B-HT290
 - morphine-withdrawal behavior
- Dopaminergic supersensitivity, 661
 - haloperidol
 - locomotor activity
 - oral administration
 - ³H-spiroperidol binding
 - stereotypy
- Dopaminergic system, 543
 - cataleptic behavior
 - cholinergic system
 - prostaglandin D₂
 - serotonergic system
- Dose-dependent effects, 305
 - ACh formation
 - DOPAC/DA ratio
 - locomotor activity
 - neurochemical actions
 - nicotine
 - time-dependent effects
- Dose differences, 821
 - d-amphetamine
 - brain monoamines
 - dopamine
 - locomotor activity, nocturnal
 - long-lasting effects
 - serotonin
 - stereotyped behavior
- Dose effects, 801
 - behavioral effects
 - caffeine
 - diazepam
 - drug interactions
 - human studies, males
- Dose related effects, 229
 - aggression
 - brain transmitters
 - footshock aggression
 - propranolol
- Dose-response
 - biphasic effects, 65
 - FK 33824, 743
 - linear running, 743
 - locomotor activity, 65
 - opioids, 743
 - strain differences, 743
 - toluene inhalation, 65
 - wheel running activity, 743
- Dose-response relationship, 757
 - adrenergic agonists
 - adrenergic antagonists
 - chickens
 - epinephrine
 - food intake
 - hepatic portal vein
 - vagotomy
- Down-regulation, 635
 - chronic administration
 - dopamine receptor binding
 - fluphenazine
 - lithium

- muscarinic receptor binding
Drinking
 acquisition and maintenance. 677
 acute administration. 431
 angiotensin II. 431
 antidipsogenic effect. 431
 benzodiazepine receptor ligands. 247
 bromocriptine. 431
 CGS 8216. 145
 cholinergic stimulation. 771
 differential effects. 145, 247
 dopamine D-1 receptors. 687
 dopamine D-2 receptors. 687
 eating. 145
 estrogen pretreatment. 431
 food deprivation. 145
 isoproterenol. 431
 isotonic saline consumption. 247
 lateral hypothalamus. 771
 M₁ muscarinic receptors. 771
 M₂ muscarinic receptors. 771
 naloxone. 677
 naltrexone. 145
 rats. males. 247
 saline acceptance-rejection. 687
 SCH 23390. 687
 schedule-induced polydipsia. 677
 sulpiride. 687
 water consumption. 247
 water deprivation. 145, 687
Drug
 AHR602. 771
 AHR6405. 771
 (+)AJ 76 (cis-(+)-5-methoxy-1-methyl-2-(n-propylamino)tetralin). 123
 alcohol. 29, 693, 749
 amantadine hydrochloride. 543
 amfonelic acid. 413
 amitriptyline. 35, 153, 313
 amphetamine. 167, 211, 413, 547, 731, 757, 765
 d-amphetamine. 7, 17, 527, 577, 827
 (+)-amphetamine. 425
 aniracetam. 183
 antazoline. 639
 apomorphine. 217, 223, 299, 413, 503, 715, 765, 771
 apomorphine hydrochloride. 77, 543
 apovincaminic acid. 183
 atrophine. 475
 atropine. 229, 327, 393, 639
 atropine methyl nitrate. 229
 atropine sulfate. 357, 543, 619
 benserazide. 407
 betaxolol. 11
 bicuculline. 71
 BM123. 475
 BMY 25.368. 683
 bramazocine. 705
 bromocriptine. 431
 caffeine. 381, 427, 801, 841
 carbachol. 771
 cathinone. 413, 547
 cesium. 235
 CGS 8216. 145, 247, 497, 709
 CGS 9896. 247, 601
 chlomidipramine. 153, 207
 chlordiazepoxide. 561, 577, 631, 709
 chlorimipramine. 207
 N-[2-chloroethyl]-N-2-bromobenzylamine. 217
 p-chlorophenylalanine. 543
 chlorpheniramine. 683
 chlorproamzine. 639
 cimetidine. 683
 clenbuterol. 11
 clomethiazole. 749
 clomipramine. 543, 593
 clonazepam. 247, 381
 clonidine. 23, 373, 421, 437, 533, 731, 791
 cocaine. 37, 211, 413, 453, 573, 835
 co-dergocrine. 95
 cola seeds. 841
 cyclazocine. 705
 4-DAMP. 771
 2-deoxy-D[1-¹⁴C]glucose. 95
 desipramine. 11, 207, 417
 desmethylinipramine. 35, 77
 diazepam. 111, 601, 801
 dicyclomine. 771
 β-diethylaminoethyl-diphenyl-propylacetate. 671
 difluoromethylornithine. 341
 L-dihydroxyphenylalanine. 543
 L-3,4-dihydroxyphenylalanine. 77
 5,6-dihydroxytryptamine. 639
 diisopropylfluorophosphate. 173, 281
 diisopropylphosphofluoridate. 813
 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate. 381
 1-(2,4-dimethoxyphenyl)-2-aminopropane. 547
 1-(3,4-dimethoxyphenyl)-2-aminopropane. 547
 dopamine. 271, 765
 dopamine hydrochloride. 77
 epinephrine. 491, 757
 eserine. 393
 estazolam. 521
 ethanol. 61, 103
 N-ethyl-acetylcholine aziridinium. 365
 ethylcholine aziridinium ion. 357
 N-ethyl-choline aziridinium. 365
 etonitazine. 749
 FG 7142. 247
 FK 33824. 743
 FLA-63
 fluphenazine. 635
 flurazepam. 521, 647
 flurothyl. 71
 formetanate. 119
 haloperidol. 1, 37, 111, 223, 241, 265, 453, 509, 661
 harmalan. 749
 harman. 749
 hemicholinium-3. 639
 hexamethonium. 119, 305
 B-HT920. 265
 Hydergine[®]. 183
 4-hydroxycyclidine. 437
 6-hydroxydopamine. 77, 203, 639
 (+)-3-[3-hydroxyphenyl]-N-n-propylpiperidine. 217
 5-hydroxytryptophan. 287
 iminodipropionitrile. 791
 imipramine. 11, 35, 111, 203, 351
 imipramine hydrochloride. 543
 impromidine. 683
 IPS-339. 11
 isoproterenol. 431
 ketamine. 23, 401
 lisurid. 265
 lithium. 235, 635
 lorazepam. 521
 LY 171555. 643, 715
 mecamlamine. 305, 393, 639
 MCNA343. 771
 mescamlamine. 119
 metergoline. 153
 methamphetamine. 547
 methcathinone. 547
 methoxamine. 373
 5-methoxy-N,N-dimethyltryptamine. 543
 1-(2-methoxy-4,5-methylene-dioxyphenyl)-2-aminopropane. 547
 N-methyl atropine. 475
 methylatropine nitrate. 619
 methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate. 381
 (3,4-methylenedioxy-methyl)-amphetamine. 401
 N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane. 425
 (+)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane. 425
 (-)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane. 425
 (±)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane. 425
 methylscopolamine. 119
 α-methyl-p-tyrosine. 291
 methysergide. 327, 639
 metoclopramide. 45, 223
 mianserin. 351
 midazolam. 749, 797
 molindine. 731
 monosodium glutamate. 503
 morphine. 45, 131, 153, 539, 565, 607, 705, 719
 muscimol. 49, 187
 myelin basic protein. 851
 naloxone. 131, 153, 167, 191, 199, 327, 437, 445, 515, 565, 705, 765, 781
 naloxone hydrochloride. 677
 naltrexone. 145, 483, 515
 nialamide. 407, 593
 nicotine. 259, 305, 393, 427
 nisoxetine. 835
 nomifensine. 77, 351
 norcocaine. 573
 norepinephrine. 131, 217, 533
 nortriptyline. 153
 oxotremorine. 173, 771
 pemoline. 183
 pentetrazol. 111
 pentobarbital. 521, 647
 pentylenetetrazol. 71, 159
 phencyclidine. 23, 401, 671, 847
 phenoxybenzamine hydrochloride. 543
 phentolamine. 327, 373, 437, 491
 1-(1-phenylcyclo-hexyl)4-hydroxypiperidine. 671, 847
 phenylephrine. 217, 373, 757
 β-phenylethylamine. 199
 1-(1-phenyl-4-hydroxycyclohexyl)piperidine. 671, 847
 phenylpropanolamine. 211, 321
 physostigmine. 229, 553
 picrotoxin. 49
 picrotoxinin. 381
 pilocarpine. 327, 635, 771
 pimozone. 731

- piperoxane, 453
 pirenzepine, 771
 potassium, 235
 prazosin, 265, 437, 791, 835
 procaine, 453
 propranolol, 229, 639
 (+)propranolol, 229
 (±)propranolol, 229
 propranolol hydrochloride, 543
 quinpirole hydrochloride, 643
³H quinuclidinyl benzilate, 671
 reserpine, 203, 287, 437, 453, 639
 ritanserin, 333
 Ro4-4601, 77
 Ro 5-4864, 381
 Ro15-1788, 111, 247, 381, 497, 631, 709, 797
 rubidium, 235
 RU 24213, 45
 salbutamol, 229, 421, 757
 SCH 23388, 715
 SCH 23390, 45, 509, 687, 715
 scopolamine, 119, 195, 313, 553, 771
 serotonin, 445
 SKF 38393, 45, 643, 715
³H-spiperone, 253
 ST-91, 437
 ST-587, 437
 sulphiride, 223, 687
 telenzepine, 771
 Δ^9 -tetrahydrocannabinol, 141, 533
 tetrahydronorharman (tetra- β -carboline), 749
 L-threo-3,4-dihydroxyphenylserine, 407
 toluene, 65
 trazolate, 111
 1-(2,4,5-trimethoxyphenyl)-2-aminopropane, 547
 d-tubocurare, 437
 (+)-UH 232 (cis-(+)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin), 123
 UM-272, 229
 vincamine, 183
 vinpocetine, 183
 yohimbine, 265, 327, 373, 421, 437, 453, 639, 731, 791
 zimelidine, 313, 351
 zopiclone, 111, 247
- Drug comparisons**
 acute administration, 601
 alcohol, 749
 alcohol preference, 749
 antidepressants, 351
 behavioral activation, 715
 behavioral effects, 841
 benzazepine enantiomers, 715
 caffeine, 841
 β -carbolines, 749
 catecholamines, 351
 catecholaminergic agonists, 731
 catecholaminergic antagonists, 731
 CGS 9896, 601
 chronic administration, 601
 cocaine, 573
 cola seeds, 841
 diazepam, 601
 DOPAC, 351
 dopamine, 351
 dopamine agonists, 715
 EEG activation, 715
- electrical brain stimulation, 731
 harmalan, 749
 ketamine, 401
 lesions, nucleus accumbens, 351
 locomotor activity, 573
 (3,4-methylenedioxy-methamphetamine), 401
 monkeys, 401
 multiple schedule of performance, 401
 muricide, 351
 norcocaine, 573
 nucleus accumbens, 351
 operant behavior, complex, 401
 phencyclidine, 401
 psychostimulants, 841
 quantitative determination, 731
 rabbits, 715
 repeated acquisition, 401
 rewarding efficacy, 731
 route of administration, 573
 SCH 23388, 715
 SCH 23390, 715
 sub-chronic treatment, 841
 tolerance, 601
 ultradian rhythm, 749
 withdrawal effects, 601
- Drug discrimination**
 amfonelic acid, 413
 dopamine agonists, 413
 methcathinone, 547
 naloxone, 199
 β -phenylethylamine, 199
 rate suppressant effects, 199
 spontaneous activity, 547
 stimulus generalization, 547
 stimulus properties, 199
- Drug interaction**
 acute administration, 153
 additive effects, 427
 amino acid precursors, 427
 amphetamine, 167
 analgesia, 153
 antidepressants, 153
 atropine, 475
 behavioral effects, 801
 benzodiazepine antagonists, 631
 BM123, 475
 caffeine, 427, 801
 catecholamine release, 427
 CGS 8216, 709
 chlordiazepoxide, 631, 709
 chronic administration, 153
 diazepam, 801
 direct enhancement, 709
 dopamine, 77, 765
 dose effects, 801
 endogenous opioid system, 153
 beta-endorphin concentrations, 153
 exploration, 631
 fixed-interval schedule, 167
 fixed-ratio schedule, 167
 habituation, 631
 human studies, males, 801
 ketamine, 23
 locomotor activity, 427, 631, 765
 N-methyl atropine, 475
 muscarinic receptor, 475
 muricide suppression, 77
 naloxone, 167
 nicotine, 427
 nomifensine, 77
 nucleus accumbens, 765
- opiates, 765
 phencyclidine, 23
 positive palatability, 709
 pre-synaptic locus, 765
 radial maze performance, 23
 reversible association, 475
 righting reflex, 23
 Ro 15-1788, 631, 709
 serotonergic system, 153
 thiamine deficiency, 77
- Drug screening, 111**
 corridor-type runway
 anxiolytic drugs
- Eating**
 anorexia, 5-HT induced, 333
 appetite, 321
 CGS 8216, 145
 differential effects, 145
 drinking, 145
 feeding behavior, 515
 food deprivation, 145
 food intake, 321
 human studies, females, 321
 5-hydroxytryptamine 333
 meal patterns, 515
 naloxone, 515
 naltrexone, 145, 515
 phenylpropranolamine, 321
 ritanserin, 333
 satiety, 515
 water deprivation, 145
- EEG activation, 715**
 behavioral activation
 benzazepine enantiomers
 dopamine agonists
 drug comparisons
 rabbits
 SCH 23388
 SCH 23390
- EEG slow wave activity, 123**
 dopamine antagonists
 dopamine autoreceptors
 motor activity
 sleep-wake activity
- Electrical activity, 357**
 behavioral effects
 ethylcholine aziridinium ion
 hippocampus
 rhythmical slow activity
- Electrical brain stimulation, 731**
 catecholaminergic agonists
 catecholaminergic antagonists
 drug comparisons
 quantitative determination
 rewarding efficacy
- Electroconvulsive shock treatment, 203**
 chronic administration
³H]DADLE binding
 6-hydroxydopamine
 imipramine
 opioid δ receptor
 reserpine
- Electrophysiological correlates, 299**
 apomorphine
 sniffing
 stereotyped behavior
- Endogenous opioid system, 153**
 acute administration
 analgesia
 antidepressants

- chronic administration
- drug interaction
- beta-endorphin concentrations
- serotonergic system
- Entopeduncular nucleus, 49
- gabergic projections, pallidal
- gabergic projections, striatal
- locomotor activity
- motivational effects
- motor effects
- muscimol
- picrotoxin
- subthalamic nucleus
- variable-interval hypothalamic self-stimulation
- ventral globus pallidus
- ventromedial thalamus
- β -Endorpin, 57
 - analgesic effect
 - oxytocin
 - tolerance
- β -Endorphin concentrations, 153
 - acute administration
 - analgesia
 - antidepressants
 - chronic administration
 - drug interaction
 - endogenous opioid system
 - serotonergic system
- Environmental complexity, 341
 - brain plasticity, experience dependent
 - difluoromethylornithine
 - environmental impoverishment
 - polyamines
- Environmental familiarity, 141
 - adaptation
 - behavioral effects
 - prior drug experience
 - delta-9-tetrahydrocannabinol
- Environmental impoverishment, 341
 - brain plasticity, experience dependent
 - difluoromethylornithine
 - environmental complexity
 - polyamines
- Epinephrine, 757
 - adrenergic agonists
 - adrenergic antagonists
 - chickens
 - dose-response relationship
 - food intake
 - hepatic portal vein
 - vagotomy
- Estrogen pretreatment, 431
 - acute administration
 - angiotensin II
 - antidipsogenic effect
 - bromocriptine
 - drinking
 - isoproterenol
- Estrous, 781
 - castration
 - conditioned place preference
 - mating behavior
 - naloxone
 - sexual reward
- Estrous cycle, 37
 - cocaine
 - haloperidol
 - neuroleptic activity
 - ovariectomy
 - self-administration
- Ethanol
 - adenylate cyclase, 693
 - attack targets, 61
 - chronic administration, 693
 - defensive behavior, 61
 - eye tracking, 103
 - group formation, 61
 - in vitro, 693
 - liquid diet, 693
 - monkey/human comparisons, 103
 - offensive behavior, 61
 - smooth pursuit eye movements, 103
 - social/agonistic interactions, 61
 - tolerance, 693
- Ethylcholine aziridinium ion, 357
 - behavioral effects
 - electrical activity
 - hippocampus
 - rhythmical slow activity
- Experimental allergic encephalomyelitis, 851
 - catecholamine concentrations
 - spleen
- Exploration, 631
 - benzodiazepine antagonists
 - chlordiazepoxide
 - drug interactions
 - habituation
 - locomotor activity
 - RO 15-1788
- Eye tracking, 103
 - ethanol
 - monkey/human comparisons
 - smooth pursuit eye movements
- Feeding behavior, 515
 - eating
 - meal patterns
 - naloxone
 - naltrexone
 - satiety
- Fixed-interval schedule, 167
 - amphetamine
 - drug interaction
 - fixed-ratio schedule
 - naloxone
- Fixed-ratio schedule, 167
 - amphetamine
 - drug interaction
 - fixed-interval schedule
 - naloxone
- FK 33824, 743
 - dose-response
 - linear running
 - opioids
 - strain differences
 - wheel running activity
- FLA-63, 407
 - benserazide
 - L-threo-3,4-dihydroxyphenylserine
 - locomotor activity
 - nialamide
 - norepinephrine levels
- [³H]Flunitrazepam binding sites, 35
 - antidepressants
 - benzodiazepine receptors
 - route of administration
- Fluphenazine, 635
 - chronic administration
 - dopamine receptor binding
 - down-regulation
 - lithium
- muscarinic receptor binding
- Flurazepam, 647
 - cats
 - pentobarbital
 - respiration
 - respiratory neurons
- Food deprivation
 - catecholamine levels, 271
 - catecholamine turnover, 271
 - CGS 8216, 145
 - differential, 145
 - drinking, 145
 - discriminative properties, 719
 - eating, 145
 - hypothalamus, 271
 - α -methyl-p-tyrosine, 271
 - morphine, 719
 - naltrexone, 145
 - reinforcing properties, 719
 - water deprivation, 145
- Food intake
 - adrenergic agonist, 757
 - adrenergic antagonists, 757
 - appetite, 321
 - chickens, 757
 - dose-response relationship, 757
 - eating, 321
 - epinephrine, 757
 - hepatic portal vein, 757
 - human studies, females, 321
 - phenylpropanolamine, 321
 - vagotomy, 757
- Footshock
 - d-amphetamine, 17
 - atropine sulfate, 619
 - concentration variations, 653
 - cyclic AMP, 619
 - immobilization, 619
 - methylatropine nitrate, 619
 - norepinephrine, 653
 - pituitary, 619
 - prolactin, 619
 - rotational behavior, 17
 - rotational bias, 17
 - sex differences, 17
 - stress, 619
 - stress, chronic, 653
- Footshock aggression, 229
 - aggression
 - brain transmitters
 - dose related effects
 - propranolol
- Forebrain, 389
 - alcohol nonpreferring rats
 - alcohol preferring rats
 - monoamine content
 - strain differences
- Formetanate, 119
 - acetylcholinesterase inhibition
 - operant behavior
 - schedule-controlled responding
- GABA agonists, 463
 - analgesia
 - GABA-transaminase inhibitors
 - noradrenergic pathways
- GABA antagonists, 71
 - seizure susceptibility
 - selective breeding
 - strain differences
- GABA levels, brain, 83

- age differences
- aggression, shock-induced
- inbred mice
- strain differences
- GABA-transaminase inhibitors, 463
- analgesia
- GABA agonists
- noradrenergic pathways
- Gabergic projections, pallidal, 49
- entopeduncular nucleus
- gabergic projections, striatal
- locomotor activity
- motivational effects
- motor effects
- muscimol
- picrotoxin
- subthalamic nucleus
- variable-interval hypothalamic self-stimulation
- ventral globus pallidus
- ventromedial thalamus
- Gabergic projections, striatal, 49
- entopeduncular nucleus
- gabergic projections, pallidal
- locomotor activity
- motivational effects
- motor effects
- muscimol
- picrotoxin
- subthalamic nucleus
- variable-interval hypothalamic self-stimulation
- ventral globus pallidus
- ventromedial thalamus
- Gastric secretion, 293
- body weight gain
- gastric ulceration
- mast cells
- stress
- zinc deficiency
- Gastric ulceration, 293
- body weight gain
- gastric secretion
- mast cells
- stress
- zinc deficiency
- Grooming, 643
- dopamine agonists
- habenula nucleus
- locomotor activity
- rearing
- Group formation, 61
- attack targets
- defensive behavior
- ethanol
- offensive behavior
- social/agonistic interactions
- H2 antagonists, 683
- histamine receptors
- locomotor activity
- Habenula nucleus, 643
- dopamine agonists
- grooming
- locomotor activity
- rearing
- Habituation
- d-amphetamine, 7
- benzodiazepine antagonists, 631
- chlordiazepoxide, 631
- drug interactions, 631
- exploration, 631
- locomotor activity, 631
- rearing, off-wall, 7
- rearing, on-wall, 7
- RO 15-1788, 631
- Haloperidol
- avoidance performance, 241
- chronic administration, 1
- cocaine, 37
- cognitive effects, 1
- dopaminergic supersensitivity, 661
- estrous cycle, 37
- latent inhibition, 241
- locomotor activity, 661
- motor effects, 1
- neuroleptic activity, 37
- oral administration, 661
- oral movements, 1
- ovariectomy, 37
- self-administration, 37
- ³H-spiroperidol binding, 661
- stereotypy, 661
- Harmalan, 749
- alcohol
- alcohol preference
- β -carbolines
- drug comparisons
- ultradian rhythm
- Hepatic portal vein, 757
- adrenergic agonists
- adrenergic antagonists
- chickens
- dose-response relationship
- epinephrine
- food intake
- vagotomy
- Heptyl, 625
- acetylcholinesterase
- cholinesterase inhibition
- locomotor activity
- memory
- physostigmine analogues
- Hibernation, 565
- circannual rhythm
- opiates
- seasonal difference
- squirrels
- thermoregulation
- Hindlimb scratching, 327
- muscarinic receptors
- neurokinins
- pilocarpine
- route of administration
- Hippocampus
- behavioral effects, 357, 421
- cholinergic activity, 553
- clonidine, 421
- electrical activity, 357
- ethylcholine aziridinium ion, 357
- intrahippocampal administration, 421
- odor aversions, 553
- rhythmical slow activity, 357
- salbutamol, 421
- taste aversions, 553
- yohimbine, 421
- Histimine receptors, 683
- H2 antagonists
- locomotor activity
- Hole board response, 207
- chlorimipramine
- desipramine
- stress
- stress-induced behavior
- voluntary drug ingestion
- Hormone
- ACTH, 277
- epinephrine, 271
- estradiol benzoate, 431
- estrogen, 393, 431
- 17- β -estradiol benzoate, 37
- 2-hydroxyestradiol, 37
- noradrenaline, 351
- norepinephrine, 271, 373, 407, 445, 613, 653, 835
- progesterone, 393
- prostaglandin D₂, 543
- testosterone, 533
- 5-HT autoreceptors, 593
- acute administration
- chronic administration
- clomipramine
- differential effects
- nialamide
- serotonin efflux
- 5-HT receptors, 287
- chronic treatment
- depression, drug induced
- reserpine
- 5-hydroxytryptophan
- Human studies, females, 321
- appetite
- eating
- food intake
- phenylpropanolamine
- Human studies, males
- acute administration, 29
- alcohol, 29
- behavioral effects, 801
- behavioral impairment, 29
- caffeine, 801
- diazepam, 801
- dose effects, 801
- drug interactions, 801
- learning, 29
- tolerance, 29
- 6-Hydroxydopamine, 203
- chronic administration
- [³H]DADLE binding
- electroconvulsive shock treatment
- imipramine
- opioid δ receptor
- reserpine
- 5-Hydroxytryptamine, 333
- anorexia, 5-HT induced
- eating
- ritanserin
- 5-Hydroxytryptophan, 287
- chronic treatment
- depression, drug induced
- reserpine
- 5-HT receptors
- Hyperglycemia, stress-induced, 491
- blood glucose responses
- plasma insulin responses
- sympathetic nervous system
- Hypophysectomy
- ACTH, 277, 503
- adrenocorticotrophic hormone, 503
- apomorphine, 503
- monosodium glutamate, 503
- penile erection, 277, 503
- yawning, 277, 503
- Hypothalamus
- acute exposure, 533

- catecholamine levels, 271
- catecholamine turnover, 271
- clonidine, 533
- DOPAC/DA ratios, 585
- food deprivation, 271
- in vitro, 533
- in vivo, 533
- α -methyl-p-tyrosine, 271
- sham feeding, 585
- sucrose, 585
- testes, 533
- testosterone, 533
- Δ^9 -tetrahydrocannabinol, 533
- Hypothermia, 373
 - anterior hypothalamus/preoptic area
 - cats
 - α -noradrenergic receptors
 - thermoregulation
- Iminodipropionitrile, 791
 - alpha-adrenoceptors
 - clonidine
 - prazosin
 - spasmodic syndrome, drug-induced
- Imipramine, 203
 - chronic administration
 - [3 H]DADLE binding
 - electronconvulsive shock treatment
 - 6-hydroxydopamine (6-OHDA)
 - opioid δ receptor
 - reserpine
- Immobilization, 619
 - atropine sulfate
 - cyclic AMP
 - footshock
 - methylatropine nitrate
 - pituitary
 - prolactin
 - stress
- Immobilization stress, 259
 - α_2 -adrenoceptors
 - β -adrenoceptors
 - chronic administration
 - muscarinic cholinceptors
 - nicotine
 - stress, repeated
- Inbred mice, 83
 - age differences
 - aggression, shock-induced
 - GABA levels, brain
 - strain differences
- Inbred strains, 381
 - caffeine
 - methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate
 - picrotoxinin
 - Ro 5-4864
 - seizure susceptibility
- Inferotemporal cortex, 89
 - neuronal membrane proteins
 - prefrontal cortex
 - visual discrimination
- Intrahippocampal administration, 421
 - behavioral effects
 - clonidine
 - hippocampus
 - salbutamol
 - yohimbine
- Intruder treatment, 577
 - d-amphetamine
 - chlordiazepoxide
- maternal aggression
 - maternal treatment
 - opponent size
- In vitro
 - acute exposure, 533
 - adenylate cyclase, 693
 - alkali metals, 235
 - chronic administration, 693
 - clonidine, 533
 - ethanol, 693
 - hypothalamus, 533
 - in vivo, 235, 533
 - liquid diet, 693
 - lithium, 235
 - mechanism of action, 235
 - superoxide dismutase, 235
 - testes, 533
 - testosterone, 533
 - Δ^9 -tetrahydrocannabinol, 533
 - tolerance, 693
- In vivo
 - acute exposure, 533
 - alkali metals, 235
 - clonidine, 533
 - cocaine, 453
 - hypothalamus, 533
 - in vitro, 235, 533
 - lithium, 235
 - mechanism of action, 235
 - monoaminergic neurotransmission, 453
 - phencyclidine, 671, 847
 - phencyclidine metabolites, 671
 - 3 H quinuclidinyl benzilate binding, 671, 847
 - superoxide dismutase, 235
 - testes, 533
 - testosterone, 533
 - Δ^9 -tetrahydrocannabinol, 533
- IPS-339, 11
 - beta-adrenergic agonists
 - β_1 receptors
 - β_2 receptors
 - betaxolol
 - chronic administration
 - clenbuterol
 - spontaneous motor activity
- Isolation distress, 483
 - pain threshold
 - sucrose
 - vocalizations
- Isoproterenol, 431
 - acute administration
 - angiotensin II
 - antidipsogenic effect
 - bromocriptine
 - drinking
 - estrogen pretreatment
- Isotonic saline consumption, 247
 - benzodiazepine receptor ligands
 - differential effects
 - drinking
 - rats, males
 - water consumption
- Jaw opening reflex, 437
 - alpha $_2$ adrenoceptors
 - clonidine
 - nociception
 - rabbit/rat comparisons
- Kappa agonist, partial, 705
 - cyclazocine
 - diuresis
 - mu-antagonist
 - non-opioid agonist
 - urinary output
- Ketamine
 - drug comparisons, 401
 - drug interactions, 23
 - (3,4-methylenedioxymethamphetamine, 401
 - monkeys, 401
 - multiple schedule of performance, 401
 - operant behavior, complex, 401
 - phencyclidine, 23, 401
 - radial maze performance, 23
 - repeated acquisition, 401
 - righting reflex, 23
- Kindling, 159
 - amygdala
 - convulsions, drug induced
 - olfactory bulb
 - pentyleneetetrazol
 - seizures
 - sensitization
- Kinetics, 313
 - age differences
 - antidepressants
 - memory, short-term
- Latent inhibition, 241
 - avoidance performance
 - haloperidol
- Lateral hypothalamus, 771
 - cholinergic stimulation
 - drinking
 - M $_1$ muscarinic receptors
 - M $_2$ muscarinic receptors
- Learning, 29
 - acute administration
 - alcohol
 - behavioral impairment
 - human studies, males
 - tolerance
- Learning and memory, 95
 - age differences
 - co-dergocrine
 - local cerebral glucose utilization
 - locus ceruleus
 - maze performance
- Lesions, 5,7-dihydroxytryptamine, 607
 - lesions, nucleus accumbens
 - self-administration, intravenous
 - serotonergic innervation
- Lesions, electrolytic, 187
 - antinociception
 - muscimol
 - self-injurious behavior
 - stereotyped behavior substantia nigra
 - superior colliculus
 - ventromedial thalamus
- Lesions, midbrain raphe nucleus, 725
 - biogenic amines
 - lesions, nucleus accumbens
 - monoamine content
 - muricide
 - olfactory bulbectomy
- Lesions, nucleus accumbens
 - antidepressants, 351
 - biogenic amines, 725
 - catecholamines, 351
 - DOPAC, 351

- dopamine, 351
- drug comparisons, 351
- lesions, 5,7-dihydroxytryptamine, 607
- lesions, midbrain raphe nucleus, 725
- monoamine content, 725
- muricide, 351, 725
- nucleus accumbens, 351
- olfactory bulbectomy, 725
- self-administration, intravenous, 607
- serotonergic innervation, 607
- Linear running, 743
 - dose-response
 - FK 33824
 - opioids
 - strain differences
 - wheel running activity
- Liquid diet, 693
 - adenylate cyclase
 - chronic administration
 - ethanol
 - in vitro
 - tolerance
- Lithium
 - alkali metals, 235
 - chronic administration, 635
 - dopamine receptor binding, 635
 - down-regulation, 635
 - fluphenazine, 635
 - in vitro, 235
 - in vivo, 235
 - mechanism of action, 235
 - muscarinic receptor binding, 635
 - superoxide dismutase, 235
- Local cerebral glucose utilization, 95
 - age differences
 - co-dergocrine
 - learning and memory
 - locus ceruleus
 - maze performance
- Locomotor activity
 - acetylcholinesterase, 625
 - ACh formation, 305
 - additive effects, 427
 - aggression, drug induced, 217
 - amino acid precursors, 427
 - amygdala, 217
 - analgesia, 539
 - benserazide, 407
 - benzodiazepine antagonists, 631
 - biphasic effects, 65
 - caffeine, 427
 - catecholamine release, 427
 - chlordiazepoxide, 631
 - cholinesterase inhibition, 625
 - cocaine, 573
 - DOPAC/DA ratio, 305
 - dopamine, 765
 - dopamine agonists, 643
 - dopaminergic supersensitivity, 661
 - dose-dependent effects, 305
 - dose-response, 65
 - drug comparisons, 573
 - drug interactions, 427, 631, 765
 - entopeduncular nucleus, 49
 - exploration, 631
 - FLA-63, 407
 - gabergic projections, pallidal, 49
 - gabergic projections, striatal, 49
 - grooming, 643
 - habenula nucleus, 643
 - habituation, 631
 - haloperidol, 661
 - heptyl, 625
 - histamine receptors, 683
 - H2 antagonists, 683
 - memory, 625
 - metabolic rate, 195
 - morphine, 539
 - motivational effects, 49
 - motor effects, 49
 - muscimol, 49
 - neurochemical actions, 305
 - nialamide, 407
 - nicotine, 305, 427
 - norcocaine, 573
 - norepinephrine, 217
 - norepinephrine levels, 407
 - nucleus accumbens, 765
 - opiates, 765
 - oral administration, 661
 - post-weaning exposure, 539
 - physostigmine analogues, 625
 - picrotoxin, 49
 - pre-synaptic locus, 765
 - pre-weaning exposure, 539
 - rearing, 643
 - RO 15-1788, 631
 - route of administration, 573
 - scopolamine, 195
 - ³H-spiroperidol binding, 661
 - stereotypy, 661
 - subthalamic nucleus, 49
 - L-threo-3,4-dihydroxyphenylserine, 407
 - time-dependent effects, 305
 - toluene inhalation, 65
 - variable-interval hypothalamic self-stimulation, 49
 - ventral globus pallidus, 49
 - ventromedial thalamus, 49
- Locomotor activity, backward walking, 45
 - catalepsy
 - morphine
 - RU 24213
 - SKF 38393
- Locomotor activity, nocturnal, 821
 - d*-amphetamine
 - brain monoamines
 - dopamine
 - dose differences
 - long-lasting effects
 - serotonin
 - stereotyped behavior
- Locus ceruleus, 95
 - age differences
 - co-dergocrine
 - learning and memory
 - local cerebral glucose utilization
 - maze performance
- Long-lasting effects, 821
 - d*-amphetamine
 - brain monoamines
 - dopamine
 - dose differences
 - locomotor activity, nocturnal
 - serotonin
 - stereotyped behavior
- Lordosis, 393
 - nicotine
 - nicotinic cholinergic transmission
 - ovariectomy
 - rats, females
 - route of administration
 - sexual receptivity
- M₁ muscarinic receptors, 771
 - cholinergic stimulation
 - drinking
 - lateral hypothalamus
- M₂ muscarinic receptors
 - cholinergic stimulation
 - drinking
 - lateral hypothalamus
- M₁ muscarinic receptors
 - cholinergic stimulation
 - drinking
 - lateral hypothalamus
- Mast cells, 293
 - body weight gain
 - gastric secretion
 - gastric ulceration
 - stress
 - zinc deficiency
- Maternal aggression, 577
 - d*-amphetamine
 - chlordiazepoxide
 - intruder treatment
 - maternal treatment
 - opponent size
- Maternal treatment, 577
 - d*-amphetamine
 - chlordiazepoxide
 - intruder treatment
 - maternal aggression
 - opponent size
- Mating behavior, 781
 - castration
 - conditioned place preference
 - estrous
 - naloxone
 - sexual reward
- Maze performance, 95
 - age differences
 - co-dergocrine
 - learning and memory
 - local cerebral glucose utilization
 - locus ceruleus
- Meal patterns, 515
 - feeding behavior
 - eating
 - naloxone
 - naltrexone
 - satiety
- Mechanism of action, 235
 - alkali metals
 - in vitro
 - in vivo
 - lithium
 - superoxide dismutase
- Memory
 - acetylcholinesterase, 625
 - cholinesterase inhibition, 625
 - heptyl, 625
 - locomotor activity, 625
 - passive avoidance, 183
 - physostigmine analogues, 625
 - retrieval, 183
 - vinpocetine, 183
- Memory, reference, 365
 - choline uptake
 - memory, working
 - N-ethyl-acetylcholine aziridinium
- Memory, short-term, 313
 - age differences
 - antidepressants
 - kinetics
- Memory, working, 365
 - choline uptake
 - memory, references

- N-ethyl-acetylcholine aziridinium
- Metabolic rate, 195
 - locomotor activity
 - scopolamine
- Methcathinone, 547
 - drug discrimination
 - spontaneous activity
 - stimulus generalization
- N-Methyl atropine, 475
 - atropine BM123
 - drug interaction
 - muscarinic receptors
 - reversible receptors
- Methylatropine nitrate, 619
 - atropine sulfate
 - cyclic AMP
 - footshock
 - immobilization
 - pituitary
 - prolactin
 - stress
- Methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate, 381
 - caffeine
 - inbred strains
 - picrotoxinin
 - Ro 5-4864
 - seizure susceptibility
- (3,4-Methylenedioxyamphetamine), 401
 - drug comparisons
 - ketamine
 - monkeys
 - multiple schedule of performance
 - operant behavior, complex
 - phencyclidine
 - repeated acquisition
- N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, 425
 - behavioral-potency comparisons
 - phenylisopropyl amines
 - schedule-controlled responding
- α -Methyl-p-tyrosine, 271
 - catecholamine levels
 - catecholamine turnover
 - food deprivation
 - hypothalamus
- Method
 - electrocorticogram, 299
 - high performance liquid chromatography with electrochemical detection, 725, 821, 851
 - high performance liquid chromatography with fluorescence detection, 427
 - high pressure liquid chromatography with electrochemical detection, 351, 607, 613
 - radioimmunoassay, 619, 661
- Midazolam, 797
 - physical dependence
 - scheduled-induced polydipsia
 - self-administration, oral
- Monkey/human comparisons, 103
 - ethanol
 - eye-tracking
 - smooth pursuit eye movements
- Monkeys
 - benzodiazepines, 521
 - chronic administration, 191
 - drug comparisons, 401
- ketamine, 401
 - (3,4-methylenedioxyamphetamine), 401
 - multiple schedule of performance, 401
 - naloxone, 191
 - norepinephrine, 835
 - operant behavior, complex, 401
 - phencyclidine, 401
 - psychomotor stimulants, 835
 - rate of responding, 191
 - reinforcing effects, 835
 - repeated acquisition, 401
 - self-administration, 521, 835
 - shock titration, 191
- Monoamine content
 - alcohol nonpreferring rats, 389
 - alcohol preferring rats, 389
 - biogenic amines, 725
 - forebrain, 389
 - lesions, midbrain raphe nucleus, 725
 - lesions, nucleus accumbens, 725
 - muricide, 725
 - olfactory bulbectomy, 725
 - strain differences, 389
- Monoamine/opioid interactions, 445
 - cross tolerance
 - naloxone
 - spinal analgesia
 - tolerance
- Monoaminergic neurotransmission, 453
 - cocaine
 - in vivo
- Monosodium glutamate, 503
 - adrenocorticotrophic hormone
 - apomorphine
 - hypophysectomy
 - penile erection
 - yawning
- Morphine
 - analgesia, 539
 - catalepsy, 45
 - discriminative properties, 719
 - food deprivation, 719
 - locomotor activity, 539
 - locomotor activity, backward walking, 45
 - post-weaning exposure, 539
 - pre-weaning exposure, 539
 - reinforcing properties, 719
 - RU 24213, 45
 - SKF 38393, 45
- Morphine-withdrawal behavior, 265
 - α_1 -adrenergic properties
 - B-HT290
 - dopaminergic properties
- Motivational effects, 49
 - entopeduncular nucleus
 - gabergic projections, pallidal
 - gabergic projections, striatal
 - locomotor activity
 - motor effects
 - muscimol
 - picrotoxin
 - subthalamic nucleus
 - variable-interval hypothalamic self-stimulation
 - ventral globus pallidus
 - ventromedial thalamus
- Motor activity, 123
 - dopamine antagonist
 - dopamine autoreceptors
 - EEG slow wave activity
 - sleep-wake activity
- Motor effects
 - chronic administration, 1
 - cognitive effects, 1
 - entopeduncular nucleus, 49
 - gabergic projections, pallidal, 49
 - gabergic projections, striatal, 49
 - haloperidol, 1
 - locomotor activity, 49
 - motivational effects, 49
 - muscimol, 49
 - oral movements, 1
 - picrotoxin, 49
 - subthalamic nucleus, 49
 - variable-interval hypothalamic self-stimulation, 49
 - ventral globus pallidus, 49
 - ventromedial thalamus, 49
- Mu-antagonist, 705
 - cyclazocine
 - diuresis
 - kappa agonist, partial
 - non-opioid agonist
 - urinary output
- Multiple schedule of performance, 401
 - drug comparisons
 - ketamine
 - (3,4-methylenedioxyamphetamine)
 - monkeys
 - operant behavior, complex
 - phencyclidine
 - repeated acquisition
- Muricide
 - antidepressants, 351
 - biogenic amines, 725
 - catecholamines, 351
 - DOPAC, 351
 - dopamine, 77, 351
 - drug comparisons, 351
 - drug interaction, 77
 - lesions, midbrain raphe nucleus, 725
 - lesions, nucleus accumbens, 351, 725
 - monoamine content, 725
 - nomifensine, 77
 - nucleus accumbens, 351
 - olfactory bulbectomy, 725
 - thiamine deficiency, 77
- Muscarinic cholinergic receptors, 259
 - α_2 -adrenoceptors
 - β -adrenoceptors
 - chronic administration
 - immobilization stress
 - nicotine
 - stress, repeated
- Muscarinic receptor binding, 635
 - chronic administration
 - dopamine receptor binding
 - down-regulation
 - fluphenazine
 - lithium
- Muscarinic receptors
 - acetylcholinesterase activity, 813
 - atropine, 475
 - BM123
 - choline acetyltransferase activity, 813
 - cross-tolerance, 173
 - diisopropylphosphofluoridate, 813
 - drug interaction, 475
 - hindlimb scratching, 327
 - N-methyl atropine, 475
 - neurokinins, 327

- nicotinic receptors, 813
- organophosphates, 173
- pilocarpine, 327
- QNB binding, 173
- recovery, 813
- reversible association, 475
- route of administration, 327
- sex differences, 813
- strain differences, 173
- tolerance, 173
- Muscimol
 - antinociception, 187
 - entopeduncular nucleus, 49
 - gabergic projections, pallidal, 49
 - gabergic projections, striatal, 49
 - lesions, electrolytic, 187
 - locomotor activity, 49
 - motivational effects, 49
 - motor effects, 49
 - picrotoxin, 49
 - self-injurious behavior, 187
 - stereotyped behavior, 187
 - substantia nigra, 187
 - subthalamic nucleus, 49
 - superior colliculus, 187
 - variable-interval hypothalamic self-stimulation, 49
 - ventral globus pallidus, 49
 - ventromedial thalamus, 49, 187
- Naloxone
 - acquisition and maintenance, 677
 - amphetamine, 167
 - castration, 781
 - chronic administration, 191
 - conditioned place preference, 781
 - cross tolerance, 445
 - drinking, 677
 - drug discrimination, 199
 - drug interaction, 167
 - eating, 515
 - estrous, 781
 - feeding behavior, 515
 - fixed-interval schedule, 167
 - fixed-ratio schedule, 167
 - mating behavior, 781
 - meal patterns, 515
 - monkeys, 191
 - monoamine/opioid interactions, 445
 - naltrexone, 515
 - β -phenylethylamine, 199
 - rate of responding, 191
 - rate suppressant effects, 199
 - satiety, 515
 - schedule-induced polydipsia, 677
 - sexual reward, 781
 - shock titration, 191
 - spinal analgesia, 445
 - stimulus properties, 199
 - tolerance, 445
- Naltrexone
 - CGS 8216, 145
 - differential effects, 145
 - drinking, 145
 - eating, 145, 515
 - feeding behavior, 515
 - food deprivation, 145
 - meal patterns, 515
 - naloxone, 515
 - satiety, 515
 - water deprivation, 145
- Neonates, 211
 - conditioned flavor aversion
 - conditioned place preference
 - odor
 - reinforcement
 - stimulant drugs
- N-ethyl-acetylcholine aziridinium, 365
 - choline uptake
 - memory, reference
 - memory, working
- Neurochemical actions, 305
 - ACh formation
 - DOPAC/DA ratio
 - dose-dependent effects
 - locomotor activity
 - nicotine
 - time-dependent effects
- Neurokinins, 327
 - hindlimb scratching
 - muscarinic receptors
 - pilocarpine
 - route of administration
- Neuroleptic activity, 37
 - cocaine
 - estrous cycle
 - haloperidol
 - ovariectomy
 - self-administration
- Neuroleptics, 223
 - autoreceptor blockade
 - dopamine receptor hypersensitivity
- Neuromodulator receptors, 829
 - [³H]cyclohexyladenosine binding
 - neurotransmitter receptors
 - stress, chronic
- Neuronal membrane proteins, 89
 - inferotemporal cortex
 - prefrontal cortex
 - visual discrimination
- Neurotransmitter receptors, 829
 - [³H]cyclohexyladenosine binding
 - neuromodulator receptors
 - stress, chronic
- Nialamide
 - acute administration, 593
 - benserazide, 407
 - chronic administration, 593
 - clomipramine, 593
 - differential effects, 593
 - L-threo-3,4-dihydroxyphenylserine, 407
 - FLA-63, 407
 - 5-HT autoreceptors, 593
 - locomotor activity, 407
 - norepinephrine levels, 407
 - serotonin efflux, 593
- Nicotinic cholinergic transmission, 393
 - lordosis
 - nicotine
 - ovariectomy
 - rats, females
 - route of administration
 - sexual receptivity
- Nicotinic receptors, 813
 - acetylcholinesterase activity
 - choline acetyltransferase activity
 - diisopropylphosphofluoridate
 - muscarinic receptors
 - recovery
 - sex differences
- Nicotine
 - ACh formation, 305
 - additive effects, 427
 - α_2 -adrenoceptors, 259
 - β -adrenoceptors, 259
 - amino acid precursors, 427
 - caffeine, 427
 - catecholamine release, 427
 - chronic administration, 259
 - DOPAC/DA ratio, 305
 - dose-dependent effects, 305
 - drug interactions, 427
 - immobilization stress, 259
 - locomotor activity, 305, 427
 - lordosis, 393
 - muscarinic cholinergic receptors, 259
 - neurochemical action, 305
 - nicotinic cholinergic transmission, 393
 - ovariectomy, 393
 - rats, females, 393
 - route of administration, 393
 - sexual receptivity, 393
 - stress, repeated, 259
 - time-dependent effects, 305
- Nociception, 437
 - α_2 adrenoceptors
 - clonidine
 - jaw opening reflex
 - rabbit/rat comparisons
- Nomifensine, 77
 - dopamine
 - drug interaction
 - muricide suppression
 - thiamine deficiency
- Non-opioid agonist, 705
 - cyclazocine
 - diuresis
 - kappa agonist, partial
 - mu-antagonist
 - urinary output
- Noradrenergic pathways, 463
 - analgesia
 - GABA agonists
 - GABA-transaminase inhibitors
- α -Noradrenergic receptors, 373
 - anterior hypothalamus/preoptic area
 - cats
 - hypothermia
 - thermoregulation
- Norcocaine, 573
 - cocaine
 - drug comparisons
 - locomotor activity
 - route of administration
- Norepinephrine
 - aggression, drug induced, 217
 - amygdala, 217
 - brain catecholamines, 613
 - catecholamine turnover, 613
 - concentration variations, 653
 - dopamine, 613
 - footshock, 653
 - locomotor activity, 217
 - monkeys, 835
 - pregnancy, 613
 - psychomotor stimulants, 835
 - reinforcing effects, 835
 - seizure susceptibility, 613
 - self-administration, 835
 - stress, chronic, 653
- Norepinephrine levels, 407
 - benserazide
 - L-threo-3,4-dihydroxyphenylserine
 - FLA-63

- locomotor activity
- norepinephrine levels
- Novelty-induced behavior, 699
- analgesia
- corticotropin-releasing hormone
- Nucleus accumbens
 - antidepressants, 351
 - catecholamines, 351
 - DOPAC, 351
 - dopamine, 351, 765
 - drug comparisons, 351
 - drug interactions, 765
 - lesions, nucleus accumbens, 351
 - locomotor activity, 765
 - nucleus accumbens, 351
 - opiates, 765
 - pre-synaptic locus, 765
- Odor, 211
 - conditioned flavor aversion
 - conditioned place preference
 - neonates
 - reinforcement
 - stimulant drugs
- Odor aversions, 553
 - cholinergic activity
 - hippocampus
 - taste aversions
- Offensive behavior, 61
 - attack targets
 - defensive behavior
 - ethanol
 - group formation
 - social/agonistic interactions
- Olfactory bulb, 159
 - amygdala
 - convulsions, drug induced
 - kindling
 - pentylentetrazol
 - seizures
 - sensitization
- Olfactory bulbectomy, 725
 - biogenic amines
 - lesions, midbrain raphe nucleus
 - lesions, nucleus accumbens
 - monoamine content
 - muricide
- Operant behavior, 119
 - acetylcholinesterase inhibition
 - formetanate
 - schedule-controlled responding
- Operant-behavior, complex, 401
 - drug comparisons
 - ketamine
 - (3,4-methylenedioxymethamphetamine)
 - monkeys
 - multiple schedule of performance
 - phencyclidine
 - repeated acquisition
- Operant responding, 509
 - avoidance
 - D1 receptors
 - SCH 23390
- Opiates
 - circannual rhythm, 565
 - dopamine, 765
 - drug interactions, 765
 - hibernation, 565
 - locomotor activity, 765
 - nucleus accumbens, 765
 - pre-synaptic locus, 765
 - seasonal difference, 565
 - squirrels, 565
 - thermoregulation, 565
- Opioid δ receptor, 203
 - chronic administration
 - [3 H]DADLE binding
 - electronconvulsive shock treatment
 - 6-hydroxydopamine
 - imipramine
 - reserpine
- Opioids, 743
 - dose-response
 - FK 33824
 - linear running
 - strain differences
 - wheel running activity
- Opponent size, 577
 - d-amphetamine
 - chlordiazepoxide
 - intruder treatment
 - maternal aggression
 - maternal treatment
- Oral administration, 661
 - dopaminergic supersensitivity
 - haloperidol
 - locomotor activity
 - 3 H-spiroperidol binding
 - stereotypy
- Oral movements, 1
 - chronic administration
 - cognitive effects
 - haloperidol
 - motor effects
- Organophosphates, 173
 - cross-tolerance
 - muscarinic receptors
 - QNB binding
 - strain differences
 - tolerance
- Ovariectomy
 - cocaine, 37
 - estrous cycle, 37
 - haloperidol, 37
 - lordosis, 393
 - neuroleptic activity, 37
 - nicotine, 393
 - nicotinic cholinergic transmission, 393
 - rats, females, 393
 - route of administration, 393
 - self-administration, 37
 - sexual receptivity, 393
- Oxytocin, 57
 - analgesic effect
 - β -endorphin
 - tolerance
- Pain threshold, 483
 - isolation distress
 - sucrose
 - vocalizations
- Palatability, 497
 - benzodiazepine receptors
 - CGS 8216
 - sham feeding
- Passive avoidance, 183
 - memory
 - retrieval
 - vinpocetine
- Penile erection
 - ACTH 277, 503
 - adrenocorticotrophic hormone, 503
 - apomorphine, 503
 - hypophysectomy, 277, 503
 - monosodium glutamate, 503
 - yawning, 277, 503
- Pentobarbital, 647
 - cats
 - flurazepam
 - respiration
 - respiratory neurons
- Pentylentetrazol, 159
 - amygdala
 - convulsions, drug induced
 - kindling
 - olfactory bulb
 - seizures
 - sensitization
- Peptide
 - adrenocorticotrophic hormone, 503
 - angiotensin II, 431
 - corticotropin-releasing hormone, 699
 - [D-Ala 2]-Met-enkephalinamide, 565
 - [D-Pro 2 ,D-Trp 6,8 ,Nle 10]-NK, 327
 - [D-Pro 2 ,D-Trp 7,9]-SP, 327
 - β -endorphin, 57
 - luteinizing hormone-releasing hormone, 533
 - oxytocin, 57
 - thyrotropin-releasing hormone, 639
- Perinatal undernutrition, 417
 - anti-immobility effect
 - chronic administration
 - desipramine
- Perseveration, 527
 - d-amphetamine
 - directional behavior
 - rotational behavior
 - spontaneous alternation
- Phencyclidine, 23
 - drug comparisons, 401
 - drug interactions, 23
 - in vivo administration, 671, 847
 - ketamine, 23, 401
 - (3,4-methylenedioxymethamphetamine), 401
 - monkeys, 401
 - multiple schedule of performance, 401
 - operant behavior, complex, 401
 - radial maze performance, 23
 - phencyclidine metabolites, 671, 847
 - repeated acquisition, 401
 - righting reflex, 23
 - 3 H quinuclidinyl benzilate binding, 671, 847
- Phencyclidine metabolites
 - in vivo, 671, 847
 - phencyclidine, 671, 847
 - 3 H quinuclidinyl benzilate binding, 671, 847
- β -Phenylethylamine, 199
 - drug discrimination
 - naloxone
 - rate suppressant effects
 - stimulus properties
- Phenylisopropylamines, 425
 - behavioral-potency comparison
 - N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane
 - schedule-controlled responding
- Phenylpropanolamine, 321
 - human studies, females
 - appetite

- eating
- food intake
- Physical dependence, 797
 - midazolam
 - scheduled-induced polydipsia
 - self-administration, oral
- Physostigmine analogues, 625
 - acetylcholinesterase
 - cholinesterase inhibition
 - heptyl
 - locomotor activity
 - memory
- Picrotoxin, 49
 - entopenduncular nucleus
 - gabergic projections, pallidal
 - gabergic projections, striatal
 - locomotor activity
 - motivational effects
 - motor effects
 - muscimol
 - subthalamic nucleus
 - variable-interval hypothalamic self-stimulation
 - ventral globus pallidus
 - ventromedial thalamus
- Picrotoxinin, 381
 - caffeine
 - inbred strains
 - methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate
 - Ro 5-4864
 - seizure susceptibility
- Pilocarpine, 327
 - hindlimb scratching
 - muscarinic receptors
 - neurokinins
 - route of administration
- Pituitary, 619
 - atropine sulphate
 - cyclic AMP
 - footshock
 - immobilization
 - methylatropine nitrate
 - prolactin
 - stress
- Plasma insulin responses, 491
 - blood glucose responses
 - hyperglycemia, stress-induced
 - sympathetic nervous system
- Polyamines, 341
 - brain plasticity, experience dependent
 - difluoromethylornithine
 - environmental complexity
 - environmental impoverishment
- Positive palatability, 709
 - CGS 8216
 - chlordiazepoxide
 - direct enhancement
 - drug interactions
 - Ro 15-1788
- Post-weaning exposure, 539
 - analgesia
 - locomotor activity
 - morphine
 - pre-weaning exposure
- Prazosin, 791
 - alpha-adrenoceptors
 - clonidine
 - iminodipropionitrile
 - spasmodic syndrome, drug induced
- Prefrontal cortex, 89
 - inferotemporal cortex
- neuronal membrane proteins
- visual discrimination
- Pregnancy, 613
 - brain catecholamines
 - catecholamine turnover
 - dopamine
 - norepinephrine
 - seizure susceptibility
- Pre-synaptic locus, 765
 - dopamine
 - drug interactions
 - locomotor activity
 - nucleus accumbens
 - opiates
- Pre-weaning exposure, 539
 - analgesia
 - locomotor activity
 - morphine
 - post-weaning exposure
- Prior drug experience, 141
 - adaptation
 - behavioral effects
 - environmental familiarity
 - delta-9-tetrahydrocannabinol
- Prolactin, 619
 - atropine sulfate
 - cyclic AMP
 - footshock
 - immobilization
 - methylatropine nitrate
 - pituitary
 - stress
- Propranolol, 229
 - aggression
 - brain transmitters
 - dose related effects
 - footshock aggression
- Prostaglandin D₂, 543
 - cataleptic behavior
 - cholinergic system
 - dopaminergic system
 - serotonergic system
- Psychostimulants, 841
 - behavioral effects
 - caffeine
 - cola seeds
 - drug comparisons
 - sub-chronic treatment
- Psychomotor stimulants, 835
 - monkeys
 - norepinephrine
 - reinforcing effects
 - self-administration
- Quantitative determination, 731
 - catecholaminergic agonists
 - catecholaminergic antagonists
 - drug comparisons
 - electrical brain stimulation
 - rewarding efficacy
- ³H Quinuclidinyl benzilate, 671
 - cross tolerance, 173
 - in vivo administration, 671, 847
 - muscarinic receptors, 173
 - organophosphates, 173
 - phencyclidine, 671, 847
 - phencyclidine metabolites, 671, 847
 - strain differences, 173
 - tolerance, 173
- Rabbits, 715
 - behavioral activation
 - benzazepine enantiomers
 - dopamine agonists
 - drug comparisons
 - EEG activation
 - SCH 23388
 - SCH 23390
- Rabbits/rat comparisons
 - alpha₂ adrenoceptors, 437
 - caudate nucleus, 253
 - clonidine, 437
 - dopamine receptors, 253
 - jaw opening reflex, 437
 - nociception, 437
 - ³H-spirperone, 253
 - ³H-spirperone binding, 253
- Radial maze performance, 23
 - drug interactions
 - ketamine
 - phencyclidine
 - righting reflex
- Rate of responding, 191
 - chronic administration
 - monkeys
 - naloxone
 - shock titration
- Rate suppressant effects, 199
 - drug discrimination
 - naloxone
 - β -phenylethylamine
 - stimulus properties
- Rate, females, 393
 - lordosis
 - nicotine
 - nicotinic cholinergic transmission
 - ovariectomy
 - route of administration
 - sexual receptivity
- Rats, males, 247
 - benzodiazepine receptor ligands
 - differential effects
 - drinking
 - isotonic saline consumption
 - water consumption
- Rearing, 643
 - dopamine agonists
 - grooming
 - habenula nucleus
 - locomotor activity
- Rearing, off-wall, 7
 - d-amphetamine
 - habituation
 - rearing, on-wall
- Rearing-on-wall, 7
 - d-amphetamine
 - habituation
 - rearing, off-wall
- Recovery, 813
 - acetylcholinesterase activity
 - choline acetyltransferase activity
 - diisopropylphosphofluoridate
 - muscarinic receptors
 - nicotinic receptors
 - sex differences
- Reinforcement, 211
 - conditioned flavor aversion
 - conditioned place preference
 - neonates
 - odor
 - stimulant drugs
- Reinforcing effects, 835
 - monkeys

- norepinephrine
- psychomotor stimulants
- self-administration
- Reinforcing properties, 719
- discriminative properties
- food deprivation
- morphine
- Repeated acquisition, 401
 - drug comparisons
 - ketamine
 - 3,4-methylenedioxyamphetamines
 - monkeys
 - multiple schedule of performance
 - operant behavior, complex
 - phencyclidine
- Reserpine
 - chronic administration, 203, 287
 - [³H]DADLE binding, 203
 - depression, drug induced, 287
 - electroconvulsive shock treatment, 203
 - 5-HT receptors, 287
 - 6-hydroxydopamine, 203
 - 5-hydroxytryptophan, 287
 - imipramine, 203
 - opioid δ receptor, 203
- Respiration, 647
 - cats
 - flurazepam
 - pentobarbital
 - respiratory neurons
- Respiratory neurons, 647
 - cats
 - flurazepam
 - pentobarbital
 - respiration
- Restraint stress, 561
 - chlordiazepoxide
 - stress tolerance
 - ulcers
- Retrieval, 183
 - memory
 - passive avoidance
 - vinpocetine
- Reversible association, 475
 - atropine
 - BM123
 - drug interaction
 - N-methyl atropine
 - muscarinic receptor
- Rewarding efficacy, 731
 - catecholaminergic agonists
 - catecholaminergic antagonists
 - drug comparisons
 - electrical brain stimulation
 - quantitative determination
- Rhythmical slow activity, 357
 - behavioral effects
 - electrical activity
 - ethylcholine aziridinium ion
 - hippocampus
- Righting reflex, 23
 - drug interactions
 - ketamine
 - phencyclidine
 - radial maze performance
- Ritanserin, 333
 - anorexia, 5-HT induced
 - eating
 - 5-hydroxytryptamine
- Ro 5-4864, 381
 - caffeine
- inbred strains
- methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate
- picrotoxinin
- seizure susceptibility
- RO 15-1788
 - benzodiazepine antagonists, 631
 - CSG 8316, 709
 - chlordiazepoxide, 631, 709
 - direct enhancement, 709
 - drug interactions, 631, 709
 - exploration, 631
 - habituation, 631
 - locomotor activity, 631
 - positive palatability, 709
- Rotational behavior
 - d-amphetamine, 17, 527
 - directional behavior, 527
 - footshock, 17
 - perseveration, 527
 - rotational bias, 17
 - sex differences, 17
 - spontaneous alternation, 527
- Rotational bias, 17
 - d-amphetamine
 - footshock
 - rotational behavior
 - sex differences
- Route of administration
 - antidepressants, 35
 - benzodiazepine receptors, 35
 - cocaine, 375
 - drug comparisons, 573
 - [³H]flunitrazepam binding sites, 35
 - hindlimb scratching, 327
 - locomotor activity, 573
 - lordosis, 393
 - muscarinic receptors, 327
 - neurokinins, 327
 - nicotine, 393
 - nicotinic cholinergic transmission, 393
 - norcocaine, 573
 - ovariectomy, 393
 - pilocarpine, 327
 - rats, females, 393
 - sexual receptivity, 393
- RU 24213, 45
 - catalepsy
 - locomotor activity, backward walking
 - morphine
 - SKF 38393
- Salbutamol, 421
 - behavioral effects
 - clonidine
 - hippocampus
 - intrahippocampal administration
 - yohimbine
- Saline acceptance-rejection, 687
 - dopamine D-1 receptors
 - dopamine D-2 receptors
 - drinking
 - SCH 23390
 - sulpiride
 - water deprivation
- Satiety, 515
 - feeding behavior
 - eating
 - meal patterns
 - naloxone
 - naltrexone
- SCH 23388, 715
 - behavioral activation
 - benzazepine enantiomers
 - dopamine agonists
 - drug comparisons
 - EEG activation
 - rabbits
 - SCH 23390
- SCH 23390
 - avoidance, 509
 - behavioral activation, 715
 - benzazepine enantiomers, 715
 - D1 receptors, 509
 - dopamine agonists, 715
 - dopamine D-1 receptors, 687
 - dopamine D-2 receptors, 687
 - drinking, 687
 - drug comparisons, 715
 - EEG activation, 715
 - operant responding, 509
 - rabbits, 715
 - saline acceptance-rejection, 687
 - SCH 23388, 715
 - sulpiride, 687
 - water deprivation, 687
- Schedule-controlled responding
 - acetylcholinesterase inhibition, 119
 - behavioral-potency comparison, 425
 - formetanate, 119
 - N-methyl-1-(3,4-methylenedioxyphenyl)-(2-aminopropane), 425
 - operant behavior, 119
 - phenylisopropylamines, 425
- Schedule-induced polydipsia
 - acquisition and maintenance, 677
 - drinking, 677
 - midazolam, 797
 - naloxone, 677
 - physical dependence, 797
 - self-administration, oral, 797
- Scopolamine, 195
 - locomotor activity
 - metabolic rate
- Seasonal difference, 565
 - circannual rhythm
 - hibernation
 - opiates
 - squirrels
 - thermoregulation
- Seizure susceptibility
 - brain catecholamines, 613
 - caffeine, 381
 - catecholamine turnover, 613
 - dopamine, 613
 - GABA antagonists, 71
 - inbred strains, 381
 - methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate, 381
 - norepinephrine, 613
 - picrotoxinin, 381
 - pregnancy, 613
 - Ro 5-4864, 381
 - selective breeding, 71
 - strain differences, 71
- Seizures, 159
 - amygdala
 - convulsions, drug induced
 - kindling
 - olfactory bulb
 - pentylentetrazol
 - sensitization
- Selective breeding, 71

- GABA antagonists
 - seizure susceptibility
 - strain differences
- Self-administration
 - benzodiazepines, 521
 - cocaine, 37
 - estrous cycle, 37
 - haloperidol, 37
 - monkeys, 521, 835
 - neuroleptic activity, 37
 - norepinephrine, 835
 - ovariectomy, 37
 - psychomotor stimulants, 835
 - reinforcing effects, 835
- Self-administration, intravenous, 607
 - lesions, 5,7-dihydroxytryptamine
 - lesions, nucleus accumbens
 - serotonergic innervation
- Self-administration, oral, 797
 - midazolam
 - physical dependence
 - scheduled-induced polydipsia
- Self-injurious behavior, 187
 - antinociception
 - lesions, electrolytic
 - muscimol
 - stereotyped behavior
 - substantia nigra
 - superior colliculus
 - ventromedial thalamus
- Sensitization, 159
 - amygdala
 - convulsions, drug induced
 - kindling
 - olfactory bulb
 - pentylentetrazol
 - seizures
- Serotonin, 821
 - d*-amphetamine
 - brain monoamines
 - dopamine
 - dose differences
 - locomotor activity, nocturnal
 - long-lasting effects
 - stereotyped behavior
- Serotonin efflux, 593
 - acute administration
 - chronic administration
 - clomipramine
 - differential effects
 - 5-HT autoreceptors
 - nialamide
- Serotonergic system, 153
 - acute administration
 - analgesia
 - chronic administration
 - drug interaction
 - endogenous opioid system
 - beta-endorphin concentrations
- Serotonergic innervation, 607
 - lesions, 5,7-dihydroxytryptamine
 - lesions, nucleus accumbens
 - self-administration, intravenous
- Serotonergic system, 543
 - cataleptic behavior
 - cholinergic system
 - dopaminergic system
 - prostaglandin D₂
- Sex differences
 - acetylcholinesterase activity, 813
 - d*-amphetamine, 17
 - choline acetyltransferase activity, 813
- diisopropylphosphofluoridate, 813
- footshock, 17
- muscarinic receptors, 813
- nicotinic receptors, 813
- recovery, 813
- rotational behavior, 17
- rotational bias, 17
- Sexual receptivity, 393
 - lordosis
 - nicotine
 - nicotinic cholinergic transmission
 - ovariectomy
 - rats, females
 - route of administration
- Sexual reward, 781
 - castration
 - conditioned place preference
 - estrous
 - mating behavior
 - naloxone
- Sham feeding
 - benzodiazepine receptors, 497
 - CGS 8216, 497
 - DOPAC/DA ratios, 585
 - hypothalamus, 585
 - palatability, 497
 - sham feeding, 585
- Shock titration, 191
 - chronic administration
 - monkeys
 - naloxone
 - rate of responding
- SKF 38393, 45
 - catalepsy
 - locomotor activity, backward walking
 - morphine
 - RU 24213
- Sleep-wake activity, 123
 - dopamine antagonists
 - dopamine autoreceptors
 - EEG slow wave activity
 - motor activity
- Smooth pursuit eye movements, 103
 - ethanol
 - eye tracking
 - monkey/human comparisons
- Sniffing, 299
 - apomorphine
 - electrophysiological correlates
 - stereotyped behavior
- Social/agonistic interactions, 61
 - attack targets
 - defensive behavior
 - ethanol
 - group formation
 - offensive behavior
- Spasmodic syndrome, drug induced, 791
 - alpha-adrenoceptors
 - clonidine
 - iminodipropionitrile
 - prazosin
- Spinal analgesia, 445
 - cross tolerance
 - monoamine/opioid interactions
 - naloxone
 - tolerance
- Spinal cord, 131
 - antinociception
 - continuous infusion
 - cross tolerance
- ³H-Spiperone, 253
 - caudate nucleus
- dopamine receptors
 - rabbit/rat comparisons
- ³H-spiperone binding
 - ³H-Spiperone binding, 253
 - caudate nucleus
 - dopamine receptors
 - rabbit/rat comparisons
 - ³H-spiperone
- ³H-Spiroperidol binding, 661
 - dopaminergic supersensitivity
 - haloperidol
 - locomotor activity
 - oral administration
 - stereotypy
- Spleen, 851
 - catecholamine concentrations
 - experimental allergic
 - encephalomyelitis
- Spontaneous activity, 547
 - drug discrimination
 - methcathinone
 - stimulus generalization
- Spontaneous alternation, 527
 - d*-amphetamine
 - directional behavior
 - perseveration
 - rotational behavior
- Spontaneous motor activity, 11
 - beta-adrenergic agonists
 - β1 receptors
 - β2 receptors
 - betaxolol
 - chronic administration
 - clenbuterol
 - IPS-339
- Squirrels, 565
 - circannual rhythm
 - hibernation
 - opiates
 - seasonal difference
 - thermoregulation
- Stereotyped behavior
 - d*-amphetamine, 827
 - antinociception, 187
 - apomorphine, 299
 - brain monoamines, 827
 - dopamine, 827
 - dose differences, 827
 - electrophysiological correlates, 299
 - lesions, electrolytic, 187
 - locomotor activity, nocturnal, 827
 - long-lasting effects, 827
 - muscimol, 187
 - self-injurious behavior, 187
 - serotonin, 827
 - sniffing, 299
 - substantia nigra, 187
 - superior colliculus, 187
 - ventromedial thalamus, 187
- Stereotypy, 661
 - dopaminergic supersensitivity
 - haloperidol
 - locomotor activity
 - oral administration
 - ³H-spiroperidol binding
- Stimulant drugs, 211
 - conditioned flavor aversion
 - conditioned place preference
 - neonaies
 - odor
 - reinforcement
- Stimulus generalization, 547

- drug discrimination
- methcathinone
- spontaneous activity
- Stimulus properties, 199
 - drug discrimination
 - naloxone
 - β -phenylethylamine
 - rate suppressant effects
- Strain differences
 - age differences, 83
 - aggression, shock-induced, 83
 - alcohol nonpreferring rats, 389
 - alcohol preferring rats, 389
 - cross-tolerance, 173
 - dose-response, 743
 - FK 33824, 743
 - forebrain, 389
 - GABA levels, brain, 83
 - GABA antagonists, 71
 - inbred mice, 83
 - linear running, 743
 - monoamine content, 389
 - muscarinic receptors, 173
 - opioids, 743
 - organophosphates, 173
 - QNB binding, 173
 - seizure susceptibility, 71
 - selective breeding, 71
 - tolerance, 173
 - wheel running activity, 743
- Stress
 - atropine sulfate, 619
 - body weight gain, 293
 - chlorimipramine, 207
 - cyclic AMP, 619
 - desipramine, 207
 - footshock, 619
 - gastric secretion, 293
 - gastric ulceration, 293
 - hole board response, 207
 - immobilization, 619
 - mast cells, 293
 - methylatropine nitrate, 619
 - pituitary, 619
 - prolactin, 619
 - stress-induced behavior, 207
 - voluntary drug ingestion, 207
 - zinc deficiency, 293
- Stress, chronic
 - concentration variations, 653
 - [³H]cyclohexyladinosine binding, 821
 - footshock, 653
 - neuromodulator receptors, 821
 - neurotransmitter receptors, 821
 - norepinephrine, 653
- Stress-induced behavior, 207
 - chlorimipramine
 - desipramine
 - hole board response
 - stress
 - voluntary drug ingestion
- Stress, repeated, 259
 - α_2 -adrenoceptors
 - β -adrenoceptors
 - chronic administration
 - immobilization stress
 - muscarinic cholinergic receptors
 - nicotine
- Stress tolerance, 561
 - chlordiazepoxide
 - restraint stress
 - ulcers
- Subacute administration, 281
 - acute administration
 - diisopropylfluorophosphate
 - tolerance development
- Sub-chronic treatment, 841
 - behavioral effects
 - caffeine
 - cola seeds
 - drug comparisons
 - psychostimulants
- Substantia nigra, 187
 - antinociception
 - lesions, electrolytic
 - muscimol
 - self-injurious behavior
 - stereotyped behavior
 - superior colliculus
 - ventromedial thalamus
- Subthalamic nucleus, 49
 - entopeduncular nucleus, 49
 - gabergic projections, pallidal
 - gabergic projections, striatal
 - locomotor activity
 - motivational effects
 - motor effects
 - muscimol
 - picrotoxin
 - subthalamic nucleus
 - variable-interval hypothalamic self-stimulation
 - ventral globus pallidus
 - ventromedial thalamus
- Sucrose
 - DOPAC/DA ratios, 585
 - hypothalamus, 585
 - isolation distress, 483
 - pain threshold, 483
 - sham feeding, 585
 - vocalizations, 483
- Sulpiride, 687
 - dopamine D-1 receptors
 - dopamine D-2 receptors
 - drinking
 - saline acceptance-rejection
 - SCH 23390
 - water deprivation
- Superior colliculus, 187
 - antinociception
 - lesions, electrolytic
 - muscimol
 - self-injurious behavior
 - stereotyped behavior
 - substantia nigra
 - ventromedial thalamus
- Superoxide dismutase, 235
 - alkali metals
 - in vitro
 - in vivo
 - lithium
 - mechanism of action
- Sympathetic nervous system, 491
 - blood glucose responses
 - hyperglycemia, stress-induced
 - plasma insulin responses
- Taste aversions, 553
 - cholinergic activity
 - hippocampus
 - odor aversions
- Testes, 533
 - acute exposure
 - clonidine
 - hypothalamus
 - in vitro
 - in vivo
 - testosterone
 - Δ^9 -tetrahydrocannabinol
- Testosterone, 533
 - acute exposure
 - clonidine
 - hypothalamus
 - in vitro
 - in vivo
 - testes
 - Δ^9 -tetrahydrocannabinol
- Δ^9 -Tetrahydrocannabinol
 - acute exposure, 533
 - adaptation, 141
 - behavioral effects, 141
 - clonidine, 533
 - environmental familiarity, 141
 - hypothalamus, 533
 - in vitro, 533
 - in vivo, 533
 - prior drug experience, 141
 - testes, 533
 - testosterone, 533
- Thermoregulation
 - anterior hypothalamus/preoptic area, 373
 - cats, 373
 - circannual rhythm, 565
 - hibernation, 565
 - hypothermia, 373
 - α -noradrenergic receptors, 373
 - opiates, 565
 - seasonal difference, 565
 - squirrels, 565
- Thiamine deficiency, 77
 - dopamine
 - drug interaction
 - muricide suppression
 - nonufensine
- L-Threo-3,4-dihydroxyphenylserine, 407
 - benserazide
 - FLA-63
 - locomotor activity
 - nialamide
 - norepinephrine levels
- Thyrotropin-releasing hormone, 639
 - cats
 - defecation
- Time-dependent effects, 305
 - ACh formation
 - DOPAC/DA ratio
 - dose-dependent effects
 - locomotor activity
 - neurochemical actions
 - nicotine
- Tolerance
 - acute administration, 29, 601
 - adenylate cyclase, 693
 - alcohol, 29, 693
 - analgesic effect, 57
 - behavioral impairment, 29
 - CGS 9896, 601
 - chronic administration, 601, 693
 - cross-tolerance, 173, 445
 - diazepam, 601
 - drug comparisons, 601
 - β -endorphin, 57
 - human studies, males, 29
 - in vitro, 693

- learning, 29
- liquid diet, 693
- monoamine/opioid interactions, 445
- muscarinic receptors, 173
- naloxone, 445
- organophosphates, 173
- oxytocin, 57
- QNB binding, 173
- spinal analgesia, 445
- strain differences, 173
- withdrawal effects, 601
- Tolerance development, 281
 - acute administration
 - diisopropylfluorophosphate
 - subacute administration
- Toluene inhalation, 65
 - biphasic effects
 - dose-response
 - locomotor activity
- Ulcers, 561
 - chlordiazepoxide
 - restraint stress
 - stress tolerance
- Ultradian rhythm, 749
 - alcohol
 - alcohol preference
 - β -carbolines
 - drug comparisons
 - harmalan
- Urinary output, 705
 - cyclazocine
 - diuresis
 - kappa agonist, partial
 - mu-antagonist
 - non-opioid agonist
- Vagotomy, 757
 - adrenergic agonists
 - adrenergic antagonists
 - chickens
 - dose-response relationship
 - epinephrine
 - food intake
 - hepatic portal vein
- Variable-interval hypothalamic self-stimulation, 49
 - entopeduncular nucleus
 - gabergic projections, pallidal
 - gabergic projections, striatal
 - locomotor activity
 - motivational effects
- motor effects
- muscimol
- picrotoxin
- subthalamic nucleus
- ventral globus pallidus
- ventromedial thalamus
- Vocalizations, 483
 - isolation distress
 - pain threshold
 - sucrose
- Voluntary drug ingestion, 207
 - chlorimipramine
 - desipramine
 - hole board response
 - stress
 - stress-induced behavior
- Vinpocetine, 183
 - memory
 - passive avoidance
 - retrieval
- Visual discrimination, 89
 - inferotemporal cortex
 - neuronal membrane proteins
 - prefrontal cortex
- Ventral globus pallidus, 49
 - entopeduncular nucleus
 - gabergic projections, pallidal
 - gabergic projections, striatal
 - locomotor activity
 - motivational effects
 - motor effects
 - muscimol
 - picrotoxin
 - subthalamic nucleus
 - variable-interval hypothalamic self-stimulation
 - ventromedial thalamus
- Ventromedial thalamus
 - antinociception, 187
 - entopeduncular nucleus, 49
 - gabergic projections, pallidal, 49
 - gabergic projections, striatal, 49
 - lesions, electrolytic, 187
 - locomotor activity, 49
 - motivational effects, 49
 - motor effects, 49
 - muscimol, 49, 187
 - picrotoxin, 49
 - self-injurious behavior, 187
 - stereotyped behavior, 187
 - substantia nigra, 187
 - subthalamic nucleus, 49
 - superior colliculus, 187
 - variable-interval hypothalamic self-stimulation, 49
 - ventral globus pallidus, 49
- Water consumption, 247
 - benzodiazepine receptor ligand
 - differential effects
 - drinking
 - isotonic saline consumption
 - rats, males
- Water deprivation
 - CGS 8216, 145
 - differential effects, 145
 - dopamine D-1 receptors, 687
 - dopamine D-2 receptors, 687
 - drinking, 145, 687
 - eating, 145
 - food deprivation, 145
 - naltrexone, 145
 - saline acceptance-rejection, 687
 - SCH 23390, 687
 - sulpiride, 687
- Wheel running activity, 743
 - dose-response
 - FK 33824
 - linear running
 - opioids
 - strain differences
- Withdrawal effects, 601
 - acute administration
 - CGS 9896
 - chronic administration
 - diazepam
 - drug comparisons
 - tolerance
- Yawning
 - ACTH, 277, 503
 - adrenocorticotrophic hormone, 5
 - apomorphine, 503
 - hypophysectomy, 277, 503
 - monosodium glutamate, 503
 - penile erection, 277, 503
- Yohimbine, 421
 - behavioral effects
 - clonidine
 - hippocampus
 - intrahippocampal administration
 - salbutamol
- Zinc deficiency, 293
 - body weight gain
 - gastric secretion
 - gastric ulceration
 - mast cells
 - stress

AUTHOR INDEX

- Abe, Y., 77
 Ahluwalia, P., 653
 Alföldi, P., 123
 Al-Khatib, Iz. M. H., 351
 Alkondon, M., 229
 Alleva, E., 539
 Alpern, H. P., 71
 Amairic, M., 765
 Anderson, S. M., 829
 Ando, K., 103
 Andrews, J. S., 167
 Anisman, H., 653
 Antkiewicz-Michaluk, L., 203
 Aprison, M. H., 287
 Argiolas, A., 503
 Axon, D. I. R., 45

 Babbini, M., 719
 Bacchi, A., 719
 Baker, R. C., 693
 Balansard, G., 841
 Baran, L., 35
 Barber, D. J., 145
 Bartoletti, M., 719
 Baum, M. J., 781
 Baumeister, A. A., 187
 Beleslin, D. B., 373, 639
 Bermúdez-Rattoni, F., 553
 Bernet, F., 421
 Berridge, K. C., 709
 Blanchard, D. C., 61
 Blanchard, R. J., 61
 Blass, E., 483
 Blundell, J. E., 515
 Boast, C. A., 601
 Boggan, W. O., 671, 847
 Booth, R. A., 475
 Boudinot, E., 647
 Bourbonais, K. A., 585
 Bowers, W., 653
 Braun, T., 791
 Brini, A., 153
 Broekkamp, C. L. E., 771
 Broitman, S. T., 207
 Brufani, M., 625
 Brugge, K. L., 287
 Büchau, C., 749
 Bushnell, P. J., 195

 Cabib, S., 83
 Cadet, J. L., 791
 Caffry, E. W., 321
 Calcagnetti, D. J., 743
 Camp, D. M., 821
 Caporali, M. G., 715
 Carlson, J. N., 17
 Carlsson, A., 123
 Carney, J. M., 381
 Cash, R., 11
 Castellano, C., 625
 Cervenko, F., 445
 Cervenko, F. W., 131
 Chai, C. Y., 427
 Champagnat, J., 647
 Chávez, A. F., 553
 Cho, C. H., 293
 Ciesielski, L., 83
 Clemens, L. G., 393
 Clement, J., 83

 Clopton, J. K., 223
 Co, C., 607
 Coburn, K. L., 553
 Cochrane, C., 491
 Collins, A. C., 173, 813
 Collu, M., 277
 Cooper, S. J., 145, 247, 497, 687
 Curtin, J. C., 223
 Curtis, A. L., 437

 Dalterio, S., 533
 Dalton, J. C. H., 37
 Danti, S., 11
 Darwish, M., 271
 Denavit-Saubie, M., 647
 DeNoble, V. J., 183
 De Paolo, L., 533
 Dietrich, R. A., 693
 Dworkin, S. I., 607
 Dykstra, L. A., 191

 Eggleston, T., 619
 Elliott, P. J., 573
 Ellison, G. D., 1
 Emm, T., 313
 Estall, L. B., 247
 Eterović, V. A., 341
 Evans, J. A. C., 643

 Falk, J. L., 797
 Faught, K., 847
 Feinglos, M. N., 491
 Feldon, J., 241
 Ferchmin, P. A., 341
 Fernández, J., 553
 Fernando, J. C. R., 281
 File, S. E., 631
 Fitzgerald, E., 483
 Flannelly, K., 61
 Fletcher, G. H., 45
 Flux, M., 381
 Flynn, J. J., 743
 Fong, L. Y. Y., 293
 Forbes, J. M., 757
 Fóscolo, M. R., 207
 Foutz, A. S., 647
 Frances, H., 11
 Fratta, W., 277, 503
 Freed, W. J., 791
 Freeman, G. B., 305
 Fregley, M. J., 431
 Frey, J. M., 661
 Freyd, G., 731
 Friedman, E., 635
 Frye, G. D., 187
 Fujiwara, M., 351, 543

 Gaiardi, M., 719
 Galen, D. M., 1
 Gallistel, C. R., 731
 Garcia, J., 553
 Gerhardt, S. C., 601
 Gertner, S. B., 683
 Gessa, G. L., 277, 503
 Gianutsos, G., 635
 Gibson, G. E., 305
 Gilbert, D. B., 687
 Giordano, M., 7

 Glennon, R. A., 425, 547
 Glick, S. D., 17
 Goeders, N. E., 607
 Gonsalves, S. F., 647
 Goode, T. L., 327
 Gordon, J. H., 223
 Goudie, A. J., 199
 Gramlich, C. A., 159
 Griffiths, R. R., 801
 Gubellini, C., 719

 Jadot, G., 841
 Jenden, D. J., 475
 Jerome, C., 585
 Jhamandas, K., 445
 Jhanwar-Uniyal, M., 271
 Johanson, C. E., 103, 521
 Johansson, A. M., 123
 Jones, B., 141
 Jørgensen, O. S., 89
 Jourdan, M. L., 565
 Jovanović-Mićić, D., 639

 Hagan, J. J., 771
 Hajós, M., 123
 Han, P. C., 813
 Hanin, I., 357
 Harder, D. R., 851
 Haubenreisser, T., 29
 Heath, R. W., 145
 Henke, P. G., 561
 Herberg, L. J., 49
 Hernandez, L. L., 253
 Hinds, P. A., 17
 Hingtgen, J. N., 287
 Hinman, D. J., 65
 Ho, B. T., 365
 Ho, I. K., 281
 Hodge, W., 141
 Holman, E. W., 211
 Holtzman, S. G., 167
 Hori, K., 61
 Hoskins, B., 281
 Howes, G. A., 757
 Huffman, R. D., 661

 Ingram, D. K., 95
 Irwin, J., 653
 Iwasaki, K., 351

 Kalin, N. H., 699
 Kalix, P., 547
 Kamiya, H., 543
 Kant, G. J., 619, 829
 Karai, N., 407
 Kataoka, Y., 351, 725
 Kato, T., 407
 Katsube, J., 407
 Katsuyama, M., 407
 Katz, Y., 241
 Kehoe, P., 483
 Keller, E. A., 417
 Kigoshi, S., 259
 Kirkham, T. C., 145, 497, 515
 Kisara, K., 77
 Kissileff, H. R., 321
 Kokkinidis, L., 527
 Koller, W. C., 223
 Konkol, R. J., 851

 Koob, G. F., 765
 Kostowski, W., 217
 Kovács, G. L., 57
 Kuhn, C. M., 491

 Landman-Roberts, L., 619
 Laviola, G., 539
 Leander, J. D., 705
 Lee, E. H. Y., 427
 Lee, T. F., 565
 Leibowitz, S. F., 271
 Leo, G. L., 851
 Lesko, L., 313
 Leu, J. R., 829
 Leventer, S. M., 557
 Levin, B. E., 271
 Levin, E. D., 1
 Li, T.-K., 389
 Lim, D.-K., 281
 Lister, R. G., 631
 Little, P. J., 425
 London, E. D., 95
 Loomis, C. W., 131, 445
 Lumeng, L., 389

 McBride, W. J., 389
 McCann, D. J., 23
 McIntyre, T. D., 71
 McMahan, T. F., 313

 Ma, P. C. C., 293
 MacPhail, R. C., 119
 Maillard, C., 841
 Mandel, P., 83
 Mantegazza, P., 153
 Margules, D. L., 743
 Marini, S., 333
 Marona-Lewicka, D., 203
 Marta, M., 625
 Martin, P., 141
 Marwah, J., 437, 453
 Massi, M., 333
 Massotti, M., 715
 Mastropaolo, J., 401
 Mauri, A., 503
 Medhurst, L. J., 173
 Melis, M. R., 503
 Meyerhoff, J. L., 619
 Michaluk, J., 203
 Middaugh, L. D., 671, 847
 Miller, R. L., 781
 Milne, B., 131, 445
 Mogensen, J., 89
 Molina, V. A., 417
 Moore, L. L., 187
 Morgan, W. W., 661
 Morin-Surun, M.-P., 647
 Mos, J., 577
 Moser, V. C., 119
 Muramatsu, I., 259
 Murphy, J. M., 389
 Myers, R. D., 373

 Naiman, N., 547
 Nakamura, M., 407
 Nemeroff, C. B., 573

 Obál, F., Jr., 123

- Offord, S. J., 593
 Ogle, C. W., 293
 Oliverio, A., 625
 Oliveto, A. H., 191
 Olivier, B., 577
 O'Neill, K. A., 683
 Ongini, E., 715
 Ono, N., 543
 Orsingher, O. A., 417
 Overstreet, D. H., 475

 Pagella, P. G., 625
 Panerai, A. E., 153
 Pavone, F., 625
 Peluso, J., 533
 Pitts, D. K., 453
 Pomponi, M., 625
 Pope, C. N., 365
 Powell, D. A., 253
 Przegaliński, E., 35
 Pucilowski, O., 217
 Puglisi-Allegra, S., 83

 Rabin, R. A., 23, 693
 Raffa, R. B., 327
 Raisman, R., 11
 Ray, A., 229
 Rennert, O. M., 381
 Renwart, N., 11
 Rezvani, A. H., 373
 Riley, A. L., 677
 Roache, J. D., 801
 Roberts, D. C. S., 37
 Robinson, T. E., 821

 Rodríguez Echandía, E. L., 207
 Roerig, D. L., 851
 Rokosz-Pelc, A., 35, 203
 Rommelspacher, H., 749
 Rosecrans, J. A., 425
 Rosen, G. M., 573
 Royal, M., 141
 Rubcsek, G., 123
 Rugarli, P. L., 625
 Russell, K. H., 7
 Russell, R. W., 475

 Sacerdote, P., 153
 Sagratella, S., 715
 Saito, R., 543
 Sakurai, Y., 725
 Samardzić, R., 639
 Sanberg, P. R., 7
 Sanger, D. J., 509
 Sawynok, J., 463
 Schechter, M. D., 413
 Schultz, C. E., 709
 Schuster, C. R., 103
 Scott, R. W., 327
 Scotto, G., 841
 Seale, T. W., 381
 Sen, P., 229
 Serra, G., 277
 Sherman, J. E., 699
 Sherman, K. A., 305
 Shukla, G. S., 235
 Shultz, K., 607
 Simansky, K. J., 585
 Simler, S., 83

 Simon, P., 11
 Skolnick, P., 381
 Smith, C. A., 211
 Smith, G. P., 585
 Smith, J. E., 607
 Smolen, A., 173, 613, 813
 Smolen, T. N., 173, 613, 813
 Spangler, E. L., 95
 Starr, M. S., 45
 Steger, R., 533
 Stewart, D. J., 357
 Stringer, A. J., 847
 Stripling, J. S., 159
 Surwit, R. S., 491
 Svensson, K., 123
 Swerdlow, N. R., 765
 Szechtman, H., 299

 Tadano, T., 77
 Tang, M., 797
 Tang, Y. P., 427
 Tani, Y., 725
 Telegdy, G., 57
 Terzić, B., 639
 Thompson, D. M., 401
 Thornton, E. W., 643
 Thornton, J. C., 321
 Ticku, M. K., 661
 Tonnaer, J. A. D. M., 771
 Treit, D., 709
 Trzaskowska, E., 217
 Tsai, M. J., 427

 Ueki, S., 111, 351, 725

 Ushio, M., 725
 Valzelli, L., 217
 van de Kamp, J. L., 613
 van der Laan, J. W., 265
 Vanderwolf, C. H., 299, 357
 van Oorschot, R., 577
 Verleye, M., 421
 Vetulani, J., 35, 203
 Vickers, G. J., 37
 Vion-Dury, J., 841
 Vogel-Sprott, M., 29

 Walovitch, R. C., 95
 Wang, L. C. H., 565
 Warwick, R. O., Jr., 593
 Weaver, D. R., 393
 Weiner, I., 241
 Weiner, M., 313
 Weiss, J., 749
 Wetherington, C. L., 677
 Wesselmann, U., 851
 Wickens, A., 643
 Williams, S. F., 49
 Winsauer, P. J., 401
 Winter, J. C., 23
 Woolverton, W. L., 835
 Wright, A. A., 365

 Yamamoto, T., 111
 Yamanaka, K., 259
 Yamashita, K., 725
 Yonezawa, A., 77
 Yousif, M., 425, 547
 Zacharko, R. M., 653